EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	576	(549/77).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/05/31 08:37
S2	1057	(514/438).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/05/31 08:37
S3	706	(548/131).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/05/31 08:37
S4	946	(514/364).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/05/31 08:37



L6 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:610159 CAPLUS Full-text
DOCUMENT NUMBER: 141:174068
TITLE: Vesicant treatment with (phenylalkyl)thiophenes as vitamin D receptor modulators
INVENTOR(S): Nagpal, Sunil
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Yee, Ying Kwong
SOURCE: PCT Int. Appl., 496 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063348	A2	20040729	WO 2004-US6	20040107
WO 2004063348	A8	20040930		
WO 2004063348	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1587905	A2	20051026	EP 2004-700549	20040107

EP 1587905 A3 20051214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2006135484 A1 20060622 US 2005-540667 20050624
PRIORITY APPLN. INFO.: US 2003-439575P P 20030110
WO 2004-US6 W 20040107
OTHER SOURCE(S): MARPAT 141:174068
GI



I



II

AB The present invention relates to a method of treating or preventing damage to human skin cells by chemical vesicants, such as mustard, by administering non-secosteroidal, title compds. I [wherein R1 and R2 = independently (fluoro)alkyl; or CR1R2 = (un)substituted carbocycle; Q1 and Q2 = C, S, with the proviso that one atom = S and the other atom = C; R3 and R4 = independently H, halo, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)alkylthio, CN, NO2, acetyl, (cyclo)alkenyl, cycloalkyl; L1 and L2 = independently a bond, (CH2)mCX1, (CH2)mCHOH, (CH2)mO, (CH2)mS, (CH2)mSO, (CH2)mSO2, (CH2)mNR5, (CH2)mC(R5)2, (CH2)mC.tplbond.C, (CH2)mCH=CH, CHOHCX1, SO2NH, SO2O, SO2CX1, NHCCX1, NHSO, CH2SO, OSO; m = 0-2; X1 = O, S;

R5 = H, (fluoro)alkyl; Z1 and Z2 = independently H, OH, halo, formyl, NO2, CN, (fluoro)phenyl, benzyl, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, acyl, carboxy, carbamoyl, alkoxy, alkylthio, sulfamoyl, (thio)ureido, amino, etc.; with provisos; and pharmaceutically acceptable salts or prodrugs thereof] with vitamin D receptor (VDR) modulating activity. Examples include prepns. and bioassays for efficacy and toxicity of representative I. For instance, reaction of 3-[4-(benzyloxy)-3- methylphenyl]-3-[4-methyl-5-(hydroxymethyl)thiophen-2-yl]pentane with PBr3 and LiHMDS, followed by addition of pinacolone gave the 5-(3-oxo-4,4- dimethylpentyl)-4-methylthiophene derivative (82%). Deprotection using Pd/C in EtOH/EtOAc provided the phenol (97%), which was alkylated with methylmercaptomethyl chloride (73%) and oxidized using m-CPBA to afford the 4-(methylsulfonylmethoxy)-3-methylphenyl derivative (33%). Reduction of the ketone using NaBH2 in MeOH yielded the alc. II (quant.). The preferred enantiomer of latter exhibited VDR activity in the RXR-VDR heterodimer assay (EC50 = 40.57 nM) and showed osteoporosis inhibition activity in the osteocalcin (OCN) promoter assay (EC50 = 46.82 nM), while demonstrating low toxicity in the mouse hypercalcemia assay (EC50 = >1000 nM). In addition, results from the keratinocyte proliferation assay (IC50 = 76 nM) and the IL-10 induction assay (IC50 = 26 nM) indicated that the preferred enantiomer of II may also be useful for the treatment of psoriasis, abscesses, and adhesions.

IT **633338-30-4P**

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(VDR modulator, chromatog. resolution; preparation of (phenylalkyl)thiophenes as VDR modulators for preventing or treating damage to human skin cells by chemical vesicants)

RN 633338-30-4 CAPLUS

CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]-, methyl ester (9CI)

(CA INDEX NAME)



IT 633338-31-5P 633338-32-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT
(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
(Uses)
(VDR modulator; preparation of (phenylalkyl)thiophenes as VDR modulators for
preventing or treating damage to human skin cells by chemical vesicants)
RN 633338-31-5 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-
thienyl]propyl]-2-methylbenzoyl]-, methyl ester, (+)- (9CI) (CA INDEX
NAME)

Rotation (+).



RN 633338-32-6 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-
thienyl]propyl]-2-methylbenzoyl]-, methyl ester, (-)-

(9CI) (CA INDEX NAME)

Rotation (-).



IT 633338-33-7P 633338-34-8P 633349-42-5P 633349-43-6P 633349-44-7P 633349-45-8P 633349-46-9P 633349-47-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(VDR modulator; preparation of (phenylalkyl)thiophenes as VDR modulators for preventing or treating damage to human skin cells by chemical vesicants)
RN 633338-33-7 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 633338-34-8 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-

thienyl]propyl]-2-methylbenzoyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 633349-42-5 CAPLUS
CN Glycine, N-[4-[1-[5-(4,4-dimethyl-3-oxopentyl)-4-methyl-2-thienyl]-1-ethylpropyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-43-6 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-44-7 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-45-8 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[4-methyl-5-(2,4,4-trimethyl-3-oxopentyl)-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-46-9 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-2,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-47-0 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-2,3,4,4-tetramethylpentyl)-4-methyl-
2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:153859 CAPLUS Full-text
DOCUMENT NUMBER: 140:368090
TITLE: Anthranilic acid based CCK1 antagonists: the 2-indole
moiety may represent a "needle" according to the
recent homonymous concept
AUTHOR(S): Varnavas, Antonio; Lassiani, Lucia; Valenta,
Valentina; Berti, Federico; Tontini, Andrea; Mennuni,
Laura; Makovec, Francesco
CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of
Trieste, Trieste, 34127, Italy
SOURCE: European Journal of Medicinal Chemistry (2004), 39(1),
85-97
CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:368090

AB Recently we described an innovative class of non-peptide CCK1 antagonists keeping appropriate pharmacophoric groups on the anthranilic acid employed as a mol. scaffold. The lead compound obtained, VL-0395, characterized by the presence of Phe and the 2-indole moiety at the C- and N-termini of anthranilic acid, resp., is endowed with submicromolar affinity towards CCK1 receptors. Thus, we have prepared and tested on CCK receptors a library of VL-0395 analogs in order to investigate the precise topol. and essential key interactions of the 2-indole group of the lead with the CCK1 receptor. The obtained results confirm that this group establishes very specific interactions with this receptor sub-site and may be viewed as a "needle" group.

IT **685141-73-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(synthesis and CCK1 antagonistic activity of VL-0395 analogs)

RN 685141-73-5 CAPLUS
CN Phenylalanine, N-[2-[(2-thienylcarbonyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



IT **685141-92-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis and CCK1 antagonistic activity of VL-0395 analogs)

RN 685141-92-8 CAPLUS
CN Phenylalanine, N-[2-[(2-thienylcarbonyl)amino]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:143094 CAPLUS Full-text
DOCUMENT NUMBER: 140:199743
TITLE: Preparation of substituted (2S)-(arylamino)-3-(biphenyl-4-yl)propionic acids as antagonists of factor IX for inhibiting the intrinsic pathway of blood coagulation
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Guo, Xiao-chuan; Christen, Daniel Peter; Gohimmukkula, Devi Reddy; Huang, Guoxiang; Rothlein, Robert; Tyagi, Sameer; Yaramasu, Tripura; Behme, Christopher
PATENT ASSIGNEE(S): Transtech Pharma, Inc., USA
SOURCE: PCT Int. Appl., 326 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004014844	A2	20040219	WO 2003-US25045	20030808
WO 2004014844	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493008	A1	20040219	CA 2003-2493008	20030808
AU 2003265398	A1	20040225	AU 2003-265398	20030808
US 2004110832	A1	20040610	US 2003-637900	20030808
US 7122580	B2	20061017		
EP 1546089	A2	20050629	EP 2003-785150	20030808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005535710	T	20051124	JP 2004-527986	20030808
CN 1703395	A	20051130	CN 2003-819267	20030808
US 2006276518	A1	20061207	US 2006-500225	20060807
PRIORITY APPLN. INFO.:			US 2002-402272P	P 20020809
			US 2003-637900	A3 20030808

WO 2003-US25045

W 20030808

OTHER SOURCE(S): MARPAT 140:199743

AB The title compds. Ar2XCH(VAr1)(CH2)cG [I; c = 0-2; G = H, CO2R1, CH2OR1, COR1, CR1:NOR2, an acid isostere (wherein R1, R2 = H, alkyl, aryl, etc.); V = (CH2)bO(CH2)a, (CH2)bNR7(CH2)a, (CH2)bO, (CH2)bNR7, (CH2)a, a bond (a = 0-2; b = 1-2; R7 = H, alkyl, aryl, etc.); X = NR8, COR8, NR8CO, etc. (R8 = H, alkyl, aryl, etc.); Ar1 = (un)substituted aryl, heteroaryl, cycloalkylaryl, etc.; Ar2 = (un)substituted aryl or heteroaryl], useful as antagonists, or more preferably, partial antagonists of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation, were prepared Thus, reacting Me 2-L-amino-3-biphenyl-4-yl-propionate with isoquinoline-3-carboxylic acid followed by hydrolysis afforded 81% 3-biphenyl-4-yl-(2S)-[(isoquinoline-3-carbonyl)amino]propionic acid. The compds. I inhibit factor IX with IC50 of less than 30 μM, and are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states. The pharmaceutical composition comprising the compound I is claimed.

IT 660827-25-8P 660827-26-9P 660828-47-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of substituted (2S)-(arylamino)-3-(biphenyl-4-yl)propionic
acids as antagonists of factor IX for inhibiting intrinsic pathway of
blood coagulation)

RN 660827-25-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, α-[[5-bromo-2-[(2-thienylcarbonyl)amino]benzoyl]amino]-2'-phenoxy-, (αS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 660827-26-9 CAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, α-[[5-bromo-2-[(2-thienylacetyl)amino]benzoyl]amino]-2'-phenoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 660828-47-7 CAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, α-[[2-[([1,1'-biphenyl]-4-ylsulfonyl)[(3-methyl-2-thienyl)methyl]amino]-5-chlorobenzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:20493 CAPLUS Full-text
DOCUMENT NUMBER: 140:94034
TITLE: Preparation of 4-[N-(thiazol-2-yl)aminomethyl]benzamides as novel glucagon antagonists/inverse agonists
INVENTOR(S): Lau, Jesper; Christensen, Inge Thoger; Madsen, Peter; Bloch, Paw; Behrens, Carsten; Kodra, Janos Kodra; Nielsen, Poul Enrico
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002480	A1	20040108	WO 2003-DK350	20030527

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003233780	A1	20040119	AU 2003-233780 20030527
EP	1519723	A1	20050406	EP 2003-727245 20030527
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP	2006500325	T	20060105	JP 2004-516507 20030527
US	2004014789	A1	20040122	US 2003-448529 20030530
US	6881746	B2	20050419	
US	2005256175	A1	20051117	US 2005-63117 20050222

PRIORITY APPLN. INFO.:

		DK 2002-1006
A	20020627	
		DK 2002-1927
A	20021217	
		DK 2001-1789
A	20011203	
		US 2002-394145P
P	20020703	
		US 2002-434255P
P	20021218	
		WO 2003-DK350
W	20030527	
		US 2003-448529
A1	20030530	

OTHER SOURCE(S): MARPAT 140:94034
GI



I



II



III

AB The title compds. [I; A = (CH2)2CO2H, II, tetrazolyl; X = a bond, CR1R2, NR1; Y = CR3, N; R1-R3 = H, alkyl; or R1 and R3 on adjacent atoms may be combined to form a double bond; E = alkyl, alkenyl, cycloalkyl, aryl, etc.; B = 2,4-thiazoyl, etc.; D = (un)substituted (hetero)aryl] that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor, were prepared E.g., a multi-step synthesis of III (starting from Fmoc-β-Ala-Wang resin), was given. Most of the tested compds. I showed IC50 values below 1000 nM when tested in one of the glucagon binding assays.

IT **643009-21-6P 643009-22-7P 643009-23-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 4-[N-(thiazol-2-yl)aminomethyl]benzamides as novel glucagon antagonists/inverse agonists)

RN 643009-21-6 CAPLUS

CN β-Alanine, N-[4-[[[2-(2-thienyl)ethyl][4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 643009-22-7 CAPLUS
CN β-Alanine, N-[4-[[[2-(2-thienyl)ethyl][4-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 643009-23-8 CAPLUS
CN β-Alanine, N-[4-[[[4-(2-fluorophenyl)-2-thiazolyl][2-(2-thienyl)ethyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:972066 CAPLUS Full-text
DOCUMENT NUMBER: 140:27753
TITLE: Preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders
INVENTOR(S): Dahnke, Karl Robert; Gajewski, Robert Peter; Jones, Charles David; Linebarger, Jared Harris; Lu, Jianliang; Ma, Tianwei; Nagpal, Sunil; Simard, Todd Parker; Yee, Ying Kwong; Bunel, Emilio Enrique; Stites, Ryan Edward
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 504 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101978	A1	20031211	WO 2003-US14539	

20030522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2485503	A1	20031211	CA 2003-2485503	20030522
AU 2003233505	A1	20031219	AU 2003-233505	20030522
BR 2003009983	A	20050222	BR 2003-9983	20030522
EP 1511740	A1	20050309	EP 2003-728782	20030522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1656089	A	20050817	CN 2003-812198	20030522
JP 2005532348	T	20051027	JP 2004-509669	20030522
IN 2004KN01967	A	20061103	IN 2004-KN1967	20041221
US 2006287536	A1	20061221	US 2006-515403	20060125
PRIORITY APPLN. INFO.:			US 2002-384151P	P 20020529
			WO 2003-US14539	W 20030522

OTHER SOURCE(S): MARPAT 140:27753
GI



I



II

AB The present invention relates to novel, nonsecosteroidal, phenylalkyl thiophene compds. (shown as I; variables defined below; e.g. 3'-[4-(2-oxo-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4- (methyl)thiophen-2-yl]pentane (II)) with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compds. are useful for treating bone disease and psoriasis. For I: R and R' = C1-C5 alkyl, C1-C5 fluoroalkyl, or together R and R' form a (un)substituted, (un)saturated carbocyclic ring having 3-8 C atoms; ring atoms Q1 and Q2 = C or S, with the proviso that one atom is S and the other atom is C; RP and RT = H, halo, C1-C5 alkyl, C1-C5 fluoroalkyl, -O-C1-C5 alkyl, -S-C1-C5 alkyl, -O-C1-C5 fluoroalkyl, -CN, -NO2, acetyl, -S-C1-C5 fluoroalkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, and C3-C5 cycloalkenyl; LP and LT are divalent linking bond, -(CH2)mC(X1)- (X1 = O, S; m = 0-2), -(CH2)mCH(OH)-, etc.; ZP and ZT = H, Ph, benzyl, fluorophenyl, C1-C5 alkyl, etc.; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, .apprx.180 example prepns. are included. For example, II was prepared in 7 steps starting from 2-hydroxy-5-bromotoluene and tert-butyldimethylsilyl chloride and involving intermediates 2-(tert-Butyldimethylsilyloxy)-5-bromotoluene, 3'-[4-(tert-Butyldimethylsilyloxy)-3-methylphenyl]pentan-3- ol, 3'-[4-(Hydroxy)-3-

methylphenyl]-3'-[4-(methyl)thiophen-2-yl]pentane, 3'-[4-(Benzyloxy)-3-methylphenyl]-3'-[4-(methyl)thiophen-2-yl]pentane, 3'-[4-(Benzyloxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4- (methyl)thiophen-2-yl]pentane, and 3'-[4-(Hydroxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4-(methyl)thiophen-2-yl]pentane with yields of 97, 72, 95, 92, 54, 100 and 85, resp. Results are tabulated for many of the example I for the following assays: RXR-VDR heterodimerization (SaOS-2 cells), VDR co-transfection (Caco-2 cells), osteocalcin promotor, mouse hypercalcemia, keratinocyte proliferation, and IL-10 induction; e.g. one enantiomer of 1-[4-[1-ethyl-1-(5-hydroxymethyl-4-methylthiophen-2- yl)propyl]-2-methylphenoxy]-3,3-dimethylbutan-2-ol exhibits an EC50 = 2.8 nM in the RXR-VDR assay compared to 3 nM for the control calcipotriol.

IT **633338-30-4P**

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate, chromatog. resolution; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

RN 633338-30-4 CAPLUS

CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **633338-31-5P** **633338-32-6P**

RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT
(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
(Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D
receptor modulators for treating bone disease, psoriasis and other
disorders)
RN 633338-31-5 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-
thienyl]propyl]-2-methylbenzoyl]-, methyl ester, (+)- (9CI) (CA INDEX
NAME)

Rotation (+).



RN 633338-32-6 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-
thienyl]propyl]-2-methylbenzoyl]-, methyl ester, (-)- (9CI) (CA INDEX
NAME)

Rotation (-).



IT 633338-33-7P 633338-34-8P 633349-42-5P
633349-43-6P 633349-44-7P 633349-45-8P
633349-46-9P 633349-47-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D
receptor modulators for treating bone disease, psoriasis and other
disorders)
RN 633338-33-7 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-
thienyl]propyl]-2-methylbenzoyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 633338-34-8 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-
thienyl]propyl]-2-methylbenzoyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 633349-42-5 CAPLUS
CN Glycine, N-[4-[1-[5-(4,4-dimethyl-3-oxopentyl)-4-methyl-2-thienyl]-1-ethylpropyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-43-6 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-44-7 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-45-8 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[4-methyl-5-(2,4,4-trimethyl-3-oxopentyl)-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-46-9 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-2,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 633349-47-0 CAPLUS
CN Glycine, N-[4-[1-ethyl-1-[5-(3-hydroxy-2,3,4,4-

tetramethylpentyl)-4-methyl-
2-thienyl]propyl]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS
AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:610410 CAPLUS Full-text
DOCUMENT NUMBER: 139:179889
TITLE: Methylene amides, particularly [(arylmethyl)amino](oxo)acetic acids, useful as modulators, and especially inhibitors, of protein tyrosine phosphatases (PTPs), and their preparation, uses, e.g., as antidiabetics, and pharmaceutical compositions.
INVENTOR(S): Swinnen, Dominique; Bombrun, Agnes; Gonzalez, Jerome; Gerber, Patrick; Pittet, Pierre-Andre
PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 346 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.

DATE

WO 2003064376	A1	20030807	WO 2003-EP808	20030127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472021	A1	20030807	CA 2003-2472021	20030127
EP 1470102	A1	20041027	EP 2003-734697	20030127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007394	A	20041109	BR 2003-7394	20030127
JP 2005516061	T	20050602	JP 2003-564000	20030127
US 2005124656	A1	20050609	US 2003-501344	20030127
CN 1633410	A	20050629	CN 2003-807036	20030127
ZA 2004005179	A	20050629	ZA 2004-5179	20040629
IN 2004DN01884	A	20070406	IN 2004-DN1884	20040701
NO 2004003520	A	20041005	NO 2004-3520	20040824
PRIORITY APPLN. INFO.:			EP 2002-100078	A 20020129

EP 2002-100410

A 20020425

WO 2003-EP808

W 20030127

OTHER SOURCE(S): MARPAT 139:179889

GI



I



II

AB Title compds. I [wherein R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl, heterocycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, (alkenyl)aryl, heteroaryl, (alkynyl)aryl, heteroaryl; R2, R3 = independently H or alkyl; Cy = aryl, heteroaryl, cycloalkyl, heterocyclyl; with the proviso that four compds. are excluded; their geometrical isomers, optically active forms as enantiomers, diastereomers and racemates, and pharmaceutically acceptable salts and active derivs.] were prepared as inhibitors of protein tyrosine phosphatases (PTPs), in particular PTP1B. Examples include over 400 invention compds., five pharmaceutical formulations, and two biol. assays. For example, II was prepared in 4 steps by amidation of 4-formylbenzoic acid with dodecylamine in THF in the presence of 4-methylmorpholine and iso-Bu chloroformate for 3 h at room temperature, reductive amination with 4-trifluoromethylbenzylamine

in DCE in the presence of NaBH(OAc)3, TEA-acylation with chlorooxoacetic acid Et ester in THF, and base-catalyzed hydrolysis of the ester. II exhibited an IC50 value of 2.224 μM for inhibition of PTP1B, 1.40 μM for GLEPP-1, 2.40 μM for SHP-1, and 2.70 μM for SHP-2 in an in vitro assay. In an in vivo postprandial glycemia model in db/db mice, II, at 20-200 mg/kg orally, decreased blood glucose level by 17% at 20 mg/kg, by 42% at 100 mg/kg, and by 48% at 200 mg/kg, with decreases in serum insulin levels of -2%, 66%, and 89%, resp. Thus, I and their formulations are useful for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS).

IT **578022-25-0P**, Oxo[[4-[[[2-(2-thienyl)ethyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [(arylmethyl)amino](oxo)acetic acids as PTP inhibitors for antidiabetics)

RN 578022-25-0 CAPLUS

CN Acetic acid, oxo[[4-[[[2-(2-thienyl)ethyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS

AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:591190 CAPLUS Full-text
DOCUMENT NUMBER: 139:149756
TITLE: Preparation of N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as EDG receptor agonists
INVENTOR(S): Doherty, George A.; Li, Zhen; Hale, Jeffrey J.; Mills, Sander G.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062248	A2	20030731	WO 2003-US1059	20030114
WO 2003062248	A3	20060302		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472713	A1	20030731	CA 2003-2472713	

20030114
JP 2005527494 T 20050915 JP 2003-562125
20030114
EP 1575964 A2 20050921 EP 2003-702110
20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2005020837 A1 20050127 US 2004-500811
20040707
PRIORITY APPLN. INFO.: US 2002-349995P
P 20020118
WO 2003-US1059
W 20030114
OTHER SOURCE(S): MARPAT 139:149756

AB The present invention encompasses prepn. of compds., A(CR1R2)nNHCHR3Ar{(R4)0-4}BC (Ar = Ph, naphthyl, etc.; A = CO2H, 1H-tetrazol-5-yl, PO3H2, PO2H2, SO3H, PO(R5)OH, R5 = C1-4 alkyl, hydroxyC1-4alkyl, Ph, COC1-3alkoxy, CH(OH)Ph, etc.; n = 2-4; R1, R2 = independently selected from H, halo, OH, CO2H, C1-6 alkyl, Ph, etc.; R3 = H, C1-4 alkyl, etc.; R4 = CO2H, C1-4 alkyl, sulfonylalkyl, alkoxy, alkoxycyclopropyl, aryl, aryloxy, etc.; C = C1-8 alkyl, C1-8 alkoxy, heterocyclyl, etc.; B = (un)substituted Ph, (un)substituted C5-16 alkyl, (un)substituted C5-16 alkenyl, (un)substituted C5-16 alkynyl, etc.), as well as the pharmaceutically acceptable salts and hydrates thereof. The compds. are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compns. and methods of use are included. Thus, reaction of 3-aminopropylphosphonic acid with 4-(decyloxy)benzaldehyde in presence of Bu4NOH and sodium cyanoborohydride in MeOH for 1h at 50° gave title compound, N-((4-decyloxy)benzyl)-3-aminopropylphosphonic acid.

IT 569684-81-7P 569684-82-8P 569684-83-9P 569684-84-0P 569684-85-1P 569684-86-2P 569684-87-3P 569684-88-4P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (benzyl)aminoalkylcarboxylates, phosphinates, phosphonates

and tetrazoles as EDG receptor agonists)

RN 569684-81-7 CAPLUS

CN Butanoic acid, 4-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-82-8 CAPLUS

CN β-Alanine, N-[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 569684-83-9 CAPLUS

CN Propanoic acid, 2-methyl-3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-84-0 CAPLUS

CN Propanoic acid, 2-hydroxy-3-[[[4-[[4-phenyl-5-

(trifluoromethyl)-2-
thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-85-1 CAPLUS
CN Hexanoic acid, 3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-
thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-86-2 CAPLUS
CN Pentanoic acid, 4-methyl-3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-
thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-87-3 CAPLUS
CN Butanoic acid, 3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-
thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-88-4 CAPLUS
CN Pentanoic acid, 5-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-
thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:590932 CAPLUS Full-text
DOCUMENT NUMBER: 139:149413
TITLE: Selective S1P1/Edg1 receptor agonists
INVENTOR(S): Doherty, George A.; Forrest, Michael J.; Hajdu, Richard; Hale, Jeffrey J.; Li, Zhen; Mandala, Suzanne M.; Mills, Sander G.; Rosen, Hugh; Scolnick, Edward M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061567	A2	20030731	WO 2003-US1120	20030114
WO 2003061567	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004058894	A1	20040325	US 2003-339380	20030109
CA 2472680	A1	20030731	CA 2003-2472680	20030114
EP 1469863	A2	20041027	EP 2003-731917	20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005070506	A1	20050331	US 2004-501176	20040712

PRIORITY APPLN. INFO.:
US 2002-349991P P 20020118
US 2002-362566P P 20020307
US 2002-382933P

P 20020523

WO 2003-US1120

W 20030114

AB The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Thus, 4-HOC6H4CHO was treated with Me(CH2)7I to give 4-Me(CH2)7OC6H4CHO which was treated with H2N(CH2)3P(O)(OH)2 to give 4-Me(CH2)7OC6H4CH2NH(CH2)3P(O)(OH)2 which had an EC50 for S1P1 agonism of 1.5 nM and for S1P3 agonism of 6.0 nM.

IT 569684-81-7P 569684-82-8P 569684-83-9P 569684-84-0P 569684-85-1P 569684-86-2P 569684-87-3P 569684-88-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino functionalized organo phosphonates or organo carboxylates as S1P1/Edg1 receptor agonists)

RN 569684-81-7 CAPLUS

CN Butanoic acid, 4-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-82-8 CAPLUS

CN β-Alanine, N-[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 569684-83-9 CAPLUS
CN Propanoic acid, 2-methyl-3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-84-0 CAPLUS
CN Propanoic acid, 2-hydroxy-3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-85-1 CAPLUS
CN Hexanoic acid, 3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-86-2 CAPLUS
CN Pentanoic acid, 4-methyl-3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-87-3 CAPLUS
CN Butanoic acid, 3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 569684-88-4 CAPLUS
CN Pentanoic acid, 5-[[[4-[[4-phenyl-5-(trifluoromethyl)-

2-
thienyl]methoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:454276 CAPLUS Full-text
DOCUMENT NUMBER: 139:36344
TITLE: Preparation of benzoylaminopropanoic acids and related compounds as glucagon receptor antagonists for treating hyperglycemia and other disorders
INVENTOR(S): Kodra, Janos Tibor; Madsen, Peter; Lau, Jesper; Jorgensen, Anker Steen; Christensen, Inge Thoger
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048109	A1	20030612	WO 2002-DK800	20021128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL,
TJ, TM, TN, TR, TT,
TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,
ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

AU	2002365622	A1	20030617	AU 2002-365622 20021128
EP	1463715	A1	20041006	EP 2002-804158 20021128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP	2005511683	T	20050428	JP 2003-549302 20021128
US	2004014789	A1	20040122	US 2003-448529 20030530
US	6881746	B2	20050419	
US	2005256175	A1	20051117	US 2005-63117 20050222

PRIORITY APPLN. INFO.:

	DK 2001-1789
A 20011203	
	DK 2002-1117
A 20020718	
	DK 2002-1006
A 20020627	
	US 2002-394145P
P 20020703	
	WO 2002-DK800
W 20021128	
	DK 2002-1927
A 20021217	
	US 2002-434255P
P 20021218	
	US 2003-448529
A1 20030530	

OTHER SOURCE(S): MARPAT 139:36344

AB Novel A-NHC(O)X-YC(E)(R1)C(R2)(R3)-Z-D (I; variables defined below; e.g. 3-[[4-[2-(biphenyl-4-yl)-4-oxo-4-(4-trifluoromethoxyphenyl)butyryl]benzoyl]amino]propionic acid) that act to antagonize the

action of the glucagon peptide hormone on the glucagon receptor are claimed. More particularly, it relates to glucagon antagonists or inverse agonists. Most I according to the examples showed IC50 values <1000 nM when tested in a glucagon binding assay; no value for any I is given. Generally, I show a higher affinity for the glucagon receptor compared to the GIP receptor. Although the methods of preparation are not claimed, >100 example prepns. of I and intermediates are included. Compds. I are claimed effective against hyperglycemia, IGT, type 2 diabetes, type 1 diabetes, dyslipidemia and obesity. For I: A = HO2C(CHR4)m(CH2)n-, 2H-tetrazol-5-yl-(CH2)n-; R1 and R2 independently are H, halogen or C1-6-alkyl, or R1 and R2 are combined to form a double bond; R3 is H, C1-6-alkyl or halogen, or R3 and R2 are combined to form a double bond to O; X is arylene or heteroarylene, which may optionally be substituted with one or two groups R6 and R7 = halogen, -CN, -CF3, -OCF3, -OCHF2, -NO2, -OR8, -NR8R9 and C1-6-alkyl. Y is -C(O)-, -O-, -NR10-, -S-, -S(O)-, -S(O)2- or -CR11R12-; Z is -C(O)(CR13R14)p-, -O(CR13R14)p-, -S(CR13R14)p-, -S(O)(CR13R14)p-, -S(O)2(CR13R14)p-, -NR15-(CR13R14)p- or -(CR13R14)p-; D is aryl or heteroaryl; E is C3-8-cycloalkyl or C4-8-cycloalkenyl, aryl, heteroaryl, aryl-C2-6-alkenyl or aryl-C2-6-alkynyl; addnl. details are given in the claims.

IT 540739-08-0P, 3-[[4-[2-(4-Bromothiophen-2-yl)-4-(3,4-dichlorophenyl)-4-oxobutyryl]benzoyl]amino]propionic acid

540739-09-1P, 3-[[4-[2-(4-Bromothiophen-2-yl)-4-(4-chloro-3-methylphenyl)-4-oxobutyryl]benzoyl]amino]propionic acid

540739-38-6P, (E)-3-[[4-[4-[3,5-Bis(trifluoromethyl)phenyl]-2-[2,2']bithiophenyl-5-yl-4-oxobut-2-enoyl]benzoyl]amino]propionic acid

540739-39-7P, (E)-3-[[4-[2-(4-Bromothiophen-2-yl)-4-oxo-4-(4-trifluoromethoxyphenyl)but-2-enoyl]benzoyl]amino]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of

benzoylaminopropanoic acids and related
compds. as glucagon receptor antagonists for
treating hyperglycemia and
other disorders)

RN 540739-08-0 CAPLUS

CN β-Alanine, N-[4-[2-(4-bromo-2-thienyl)-4-(3,4-dichlorophenyl)-1,4-
dioxobutyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 540739-09-1 CAPLUS

CN β-Alanine, N-[4-[2-(4-bromo-2-thienyl)-4-(4-chloro-3-methylphenyl)-
1,4-dioxobutyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 540739-38-6 CAPLUS
CN β-Alanine, N-[4-[(2E)-4-[3,5-bis(trifluoromethyl)phenyl]-2-[2,2'-bithiophen]-5-yl-1,4-dioxo-2-butenyl]benzoyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 540739-39-7 CAPLUS
CN β-Alanine, N-[4-[(2E)-2-(4-bromo-2-thienyl)-1,4-dioxo-4-[4-(trifluoromethoxy)phenyl]-2-butenyl]benzoyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES

AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:534073 CAPLUS Full-text
DOCUMENT NUMBER: 137:93741
TITLE: Preparation of N-isoxazolyl aryl-substituted thienyl-, furyl-, and pyrrolylsulfonamides and derivatives as endothelin activity modulators
INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Blok, Natalie
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 59 pp., Cont.-in-part of U.S. 5,962,490.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6420567	B1	20020716	US 1997-938325	19970926
US 5962490	A	19991005	US 1996-721183	19960927
AU 9935803	A	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		
US 2002091272	A1	20020711	US 2001-11610	20011105
US 6632829	B2	20031014		
US 2003208084	A1	20031106	US 2003-447763	20030528

PRIORITY APPLN. INFO.: US 1996-721183 A2 19960927
US 1987-100865 A2 19870925
US 1990-416199 A2 19900515
US 1993-65202

B2 19930520
US 1993-100125
B2 19930730
US 1993-100565
A2 19930730
US 1993-142159
A2 19931021
US 1993-142552
A2 19931021
US 1993-142631
B2 19931021
US 1994-222287
A2 19940405
US 1994-247072
A2 19940520
US 1995-417075
A2 19950404
US 1995-477223
A2 19950606
AU 1996-55367
A 19960404
WO 1996-US4759
A2 19960404
US 1997-938325
A3 19970926
US 2001-11610
A3 20011105
OTHER SOURCE(S): MARPAT 137:93741
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Thienyl-, furyl-, and pyrrolylsulfonamides, formulations of pharmaceutically acceptable salts thereof, and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, disclosures include N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar2SO2NHAr1 [I; wherein Ar1 = (un)substituted monocyclic or polycyclic

heteroaryl, particularly isoxazolyl; Ar2 = G1 or G2; M = (CH2)mCO(CH2)n, (CH2)mCONH(CH2)n, (CH2)mCH:CH(CH2)n, (CH2)mCO(CH2)pNH(CH2)n, C:N(OH)(CH2)n, (CH2)mCO(CH:CH)pNH(CH2)n,CH(OH)(CH2)n, CH(CH)CO(CH2)n, CH(CH3)CO(CH2)mCH:CH(CH2)n, (CH2)n, (CH2)nO, CH2SO0-2, or CO2; m, n, and p = independently 0-6; R1-R5 = independently H, OH, NO2, CN, halo, alkyl, alkenyl, alkynyl, (hetero)aryl, arylalkyl, alkylamino, alkylthio, haloalkyl, alkoxy, alkylsulfonyl, (un)substituted amino, carbamoyl, etc.; or 2 adjacent R1-R5 form alkylenedioxy, alkylenethioxyoxy, or alkylenedithioxy; with provisos; X = S, O, or NR11; R11 = H, (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, heterocyclyl, aralkyl, aralkoxy, alkylalkenyl, alkylalkynyl, OH, CN, acyl, acyloxy, carboxy, SH, NHOH, (un)substituted amino, carbamoyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include hypertension, cardiovascular disease, asthma, hypertension, inflammatory disease, glaucoma, etc. Twenty synthetic examples are given, and numerous example compds. were prepared, tested, and/or claimed. For instance, 3-cyanomethyl-2,4,6-trimethylaniline was treated with H2SO4 in MeOH to give Me 3-amino-2,4,6-trimethylphenylacetate (88%). Amidation with N-(4-chloro-3-methyl-5-isoxazolyl)-3-sulfamoylthiophene-2-carboxylic acid using 1,1'-carbonyldiimidazole in DMF afforded II (15%). The similarly prepared title compound III exhibited IC50 values of 0.0015 ± 0.0014 μM for ETA receptors and 0.324 ± 0.78 μM for ETB receptors. Claimed compds. also exhibited improved oral half-life, bioavailability, and/or in vivo activity over those disclosed previously.

IT **205516-75-2P**, N-[3-[3-(4-Chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thienylcarboxamido]-2,4,6-trimethylbenzoyl]glutamic acid

205516-76-3P, N-[3-[3-(4-Chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thienylcarboxamido]-2,4,6-trimethylbenzoyl]aspartic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(endothelin modulator; preparation of N-isoxazolyl

aryl-substituted
thienyl-, furyl-, and pyrrolylsulfonamides and
derivs. as endothelin
activity modulators)
RN 205516-75-2 CAPLUS
CN L-Glutamic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-
isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-
2,4,6-
trimethylbenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205516-76-3 CAPLUS
CN L-Aspartic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-
isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-
2,4,6-
trimethylbenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:502825 CAPLUS Full-text
DOCUMENT NUMBER: 137:63237
TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T.; Devasthale, Pratik; Jeon, Yoon; Chen, Sean; Zhang, Hao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 190 pp., Cont.-in-part of U.S. Ser. No. 664,598.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6414002	B1	20020702	US 2001-812960	20010320
EP 1589006	A1	20051026	EP 2005-10760	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2003069275	A1	20030410	US 2002-80965	20020222
US 6919358	B2	20050719		
US 2003087935	A1	20030508	US 2002-81075	20020222
US 6727271	B2	20040427		
US 2003096846	A1	20030522	US 2002-80981	20020222
US 6653314	B2	20031125		

US 2004171644	A1	20040902	US 2003-655876 20030905
US 7084162	B2	20060801	
US 2004147560	A1	20040729	US 2003-737210 20031216
US 7053106	B2	20060530	
US 2005119311	A1	20050602	US 2004-964395 20041013
US 2007015797	A1	20070118	US 2005-155965 20050822

PRIORITY APPLN. INFO.:
US 1999-155400P P 19990922
US 2000-664598 A2 20000918
EP 2000-965172 A3 20000919
US 2001-812960 A3 20010320
US 2002-80965 A3 20020222
US 2002-80981 A3 20020222
US 2002-81075 A3 20020222
US 2003-655876 A3 20030905

OTHER SOURCE(S): MARPAT 137:63237

GI



I



II

AB Title compds. I [wherein Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H,

alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2] were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). For example, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0°-room temperature to give 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde (65%). Addition of N-benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane afforded the benzylamine derivative (55%), which was stirred with aqueous NaOH in MeOH for 14 h to give the title compound II (71%). I are useful for the treatment of diabetes, especially Type II diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases (no data).

IT **331740-62-6P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-thienyloxy)phenyl]methyl]-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331740-62-6 CAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-thienyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:792340 CAPLUS Full-text
DOCUMENT NUMBER: 135:331672
TITLE: Preparation of methionine derivatives as inhibitors of protein isoprenyl transferases
INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; O'connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorenson, Bryan K.; Sullivan, Gerard M.; Tasker, Andrew S.; Wasicak, James T.; Nelson, Lissa T. J.; Henry, Kenneth J.; Wang, Le
PATENT ASSIGNEE(S): University of Pittsburgh, USA
SOURCE: U.S., 514 pp., Cont.-in-part of U.S. Ser. No. 852,858, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6310095	B1	20011030	US 1998-73794	19980507
ZA 9906763	A	20000515	ZA 1999-6763	19991027

PRIORITY APPLN. INFO.: US 1995-7247P P 19951106
US 1996-740909 B2 19961105
US 1997-852858

B2 19970507

US 1998-73794

A 19980507

US 1998-197279

A 19981120

OTHER SOURCE(S): MARPAT 135:331672

AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is L4NR5L5 where L4 and L5 are absent or alkylene, R5 is H, alkanoyl, alkoxy, alkoxyalkyl, haloalkyl, etc.; Z is a covalent bond; R3 = cycloalkyl, alkoxy, alkyl, halogen, oxo, etc.] or their pharmaceutically acceptable salts, were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-[(R)-thiazolidin-4-ylcarbonylamino]-2- phenylbenzoyl]methionine Me ester hydrochloride, prepared via amidation reaction, showed 92% inhibition of farnesyl transferase at 1x10-6 M.

IT 216229-74-2P 216229-83-3P 216232-14-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of methionine derivs. as inhibitors of protein isoprenyl transferases)

RN 216229-74-2 CAPLUS

CN Butanoic acid, 4-(methylsulfonyl)-2-[[[5-[[(2-thienylmethyl)amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216229-83-3 CAPLUS

CN Butanoic acid, 4-(methylsulfonyl)-2-[[[5-[[[2-(2-thienyl)ethyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, (2S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216232-14-3 CAPLUS
CN 3-Thiophenecarboxylic acid, 4-[[[6-[[[(1S)-1-carboxy-3-
(methylthio)propyl]amino]carbonyl]-2'-methyl[1,1'-biphenyl]-3-
yl]methyl]amino]-, 3-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:507533 CAPLUS Full-text
DOCUMENT NUMBER: 135:102580
TITLE: Pharmaceutical and veterinary uses of endothelin antagonists for treatment of laminitis and other conditions, and preparation

thereof
INVENTOR(S): Brock, Thomas A.; Ward, Patrick R.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049289	A1	20010712	WO 2000-US35280	20001227
W: AE, AG, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001024567	A5	20010716	AU 2001-24567	20001227

PRIORITY APPLN. INFO.: US 1999-174125P P 19991231
WO 2000-US35280 W 20001227
OTHER SOURCE(S): MARPAT 135:102580

AB Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods are also provided for the treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and

metabolic bone disorders; climacteric disorders, including hot flushes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders associated with the reduction in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists.

IT 350225-46-6 350225-47-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction; endothelin antagonists for veterinary or pharmaceutical use in treatment of laminitis and other conditions)

RN 350225-46-6 CAPLUS
CN L-Glutamic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-2,4,6-trimethylbenzoyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x Na

RN 350225-47-7 CAPLUS
CN L-Aspartic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-2,4,6-

trimethylbenzoyl]-, sodium salt (9CI) (CA INDEX NAME) Absolute stereochemistry.



●x Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:472696 CAPLUS Full-text
DOCUMENT NUMBER: 135:76783
TITLE: Preparation of furan and thiophene amidine derivatives useful as inhibitors of nitric oxide synthase
INVENTOR(S): Chen, Deborah; Empfield, James; Macdonald, James; Mattes, Kenneth; Murray, Robert; Phillips, Eifion; Schmitthenner, Hans
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046171	A1	20010628	WO 2000-SE2540	20001214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002137750	A1	20020926	US 2001-763838	20010227

PRIORITY APPLN. INFO.: SE 1999-4677 A 19991220

WO 1999-SE2540 W 20001214

OTHER SOURCE(S): CASREACT 135:76783; MARPAT 135:76783

GI



I



II



III

AB There are provided novel compds. (shown as I; e.g. N-[3-[[(2R)-2- (hydroxymethyl)pyrrolidinyl]methyl]-4-methoxyphenyl]thiophene-2- carboximidamide) and optical isomers, racemates and tautomers thereof and pharmaceutically acceptable salts thereof, together with processes for their preparation, compns. containing them and their use in therapy. The compds. are inhibitors (no data) of the enzyme nitric oxide synthase, especially the neuronal isoform of nitric oxide synthase. In I, Z = furan or thiophene ring, optionally substituted by ≥1 halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, hydroxy, amino, S(O)qR4, CO2R5 and CONR6R7; X = C1-6 alkyl; Y = O, S(O)n or NR3; n and q independently = 0-2; R1 = H, halogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkoxy-O-R8, C1-6 alkoxy-NR9R10 or O-phenyl; said Ph being optionally substituted by ≥1 halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, hydroxy and amino; R2 represents C1-6 alkyl-O-R11 or C1-6 alkyl-NR12R13; R3 = H, C1-6 alkyl, C2-7 alkanoyl, C1-6 alkyl-O-R, C1-6 alkyl-NR15R16 or CH2-phenyl; said Ph being optionally substituted by ≥1 halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, hydroxy and amino; or the group NR2R3 represents azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl optionally 4-substituted by C1-6 alkyl; each of said azacyclic rings being substituted by O-R17, NR18R19, C1-6 alkyl-O-R17 or C1-6 alkyl-NR18R19 or, when Y = NR3, the groups X and R3 are joined together such that the group X-N-R3 represents a saturated 4 to 7 membered azacyclic ring; R4-R19 independently = H or C1-6 alkyl; or the groups NR9R10, NR12R13, NR15R16 and NR18R19 independently = azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl; or piperazinyl optionally 4-substituted by C1-6 alkyl. The claimed compds. are claimed to be useful for treating, or reducing the risk of hypoxia, stroke, Parkinson's disease, ischemia, neurodegenerative conditions, schizophrenia, anxiety, pain or migraine. Claimed methods of preparing I comprise (a) reacting II or a salt thereof with HN:CZL or a salt thereof (L = a leaving group); or (b) reacting III or a salt thereof (L1 = leaving group) with HYR2 or a salt thereof; or (c) preparing I (X = CH2) by reduction of a corresponding compound wherein X = C(O). 43 Example prepns. are given, but all are for thiophene derivs.

IT 346732-52-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of furan and thiophene amidine derivs. useful as
inhibitors of nitric oxide synthase)
RN 346732-52-3 CAPLUS
CN Glycine, N-cyclopropyl-N-[[5-[(imino-2-thienylmethyl)amino]-2-
methoxyphenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:228872 CAPLUS Full-text
DOCUMENT NUMBER: 134:266299
TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as
antidiabetic and antiobesity agents.
INVENTOR(S): Cheng, Peter T. W.; Devasthale, Pratik; Jeon, Yoon T.;
Chen, Sean; Zhang, Hao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	---	---	---

WO 2001021602 A1 20010329 WO 2000-US25710 20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
TW 260321 B 20060821 TW 2000-89119155 20000918
CA 2388452 A1 20010329 CA 2000-2388452 20000919
CA 2388452 C 20070403
EP 1218361 A1 20020703 EP 2000-965172 20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
BR 2000014189 A 20020820 BR 2000-14189 20000919
TR 200200732 T2 20021021 TR 2002-732 20000919
JP 2003509503 T 20030311 JP 2001-524981 20000919
HU 200204416 A2 20030428 HU 2002-4416 20000919
NZ 516820 A 20041126 NZ 2000-516820 20000919
AU 782031 B2 20050630 AU 2000-75935 20000919
EP 1589006 A1 20051026 EP 2005-10760 20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY
RU 2279427 C2 20060710 RU 2002-108928 20000919
IN 2002DN00107 A 20070406 IN 2002-DN107

20020128
ZA 2002000937 A 20030502 ZA 2002-937
20020201
NO 2002001408 A 20020514 NO 2002-1408
20020321
NO 322500 B1 20061016
PRIORITY APPLN. INFO.: US 1999-155400P
P 19990922
EP 2000-965172
A3 20000919
WO 2000-US25710
W 20000919
OTHER SOURCE(S): MARPAT 134:266299
GI



I



II

AB Title compds. [I; Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2], were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). Thus, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0°-room temperature to give 65% 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde. This was stirred 12 h with N-

benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane to give 55% benzylamine derivative, which was stirred 14 h with aqueous NaOH in MeOH to give 71% title compound (II).

IT 331740-62-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331740-62-6 CAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-thienyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:195207 CAPLUS Full-text

DOCUMENT NUMBER: 134:237827

TITLE: Inhibitors of protein isoprenyl transferases

INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.;

Sorensen, Bryan K.; Sullivan, Andrew S.; Wasicak, James T.; Henry, Kenneth J.; Wang, Le; Liu, Indrani W.

PATENT ASSIGNEE(S): University of Pittsburgh, USA

SOURCE: U.S., 442 pp., Cont.-in-part of U.S. Ser. No. 852,858, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6204293	B1	20010320	US 1998-73807	19980507

PRIORITY APPLN. INFO.: US 1995-7247P P 19951106

US 1996-740909 B2 19961105

US 1997-852858 B2 19970507

OTHER SOURCE(S): MARPAT 134:237827

AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is absent or is L4OL5, where L4 and L5 are absent or (un)substituted alkylene or alkenylene, with the proviso that at least one of L4 and L5 is not absent; Z is a covalent bond; R3 is (un)substituted aryl or cycloalkyl, cycloalkenyl] were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-(2-thienylmethoxymethyl)-2-(2-methylphenyl)benzoyl]methionine lithium salt, prepared via amidation reaction, showed 96% inhibition of farnesyltransferase at 1x10-6 M.

IT 216088-62-9P 216088-63-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(inhibitors of protein isoprenyl transferases)
RN 216088-62-9 CAPLUS
CN L-Methionine, N-[[2'-methyl-5-[(2-thienylmethoxy)methyl][1,1'-biphenyl]-2-yl]carbonyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

RN 216088-63-0 CAPLUS
CN L-Methionine, N-[[2'-methyl-5-[(3-thienylmethoxy)methyl][1,1'-biphenyl]-2-yl]carbonyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

IT 216086-56-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(inhibitors of protein isoprenyl transferases)
RN 216086-56-5 CAPLUS
CN L-Methionine, N-[[2'-methyl-5-[(2-thienylmethoxy)methyl][1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:824211 CAPLUS Full-text
DOCUMENT NUMBER: 134:4764
TITLE: Preparation of 3-(benzoylamino)propionic acid derivatives as glucagon antagonists/inverse agonists
INVENTOR(S): Ling, Anthony; Plewe, Michael Bruno; Truesdale, Larry Kenneth; Lau, Jesper; Madsen, Peter; Sams, Christian; Behrens, Carsten; Vagner, Josef; Christensen, Inge Thoger; Lundt, Behrend Frederik; Sidelmann, Ulla Grove; Thogersen, Henning
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 564 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO. DATE
WO 2000069810	A1	20001123	WO 2000-DK264 20000516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6503949	B1	20000516	US 2000-572553 20000516
CA 2373892	A1	20001123	CA 2000-2373892 20000516
EP 1183229	A1	20020306	EP 2000-926725 20000516
EP 1183229	B1	20051026	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000010651	A	20020319	BR 2000-10651 20000516
HU 200201033	A2	20020729	HU 2002-1033 20000516
JP 2002544254	T	20021224	JP 2000-618228 20000516
AT 307798	T	20051115	AT 2000-926725 20000516
ES 2250128	T3	20060416	ES 2000-926725 20000516
ZA 2001008560	A	20020613	ZA 2001-8560 20011018
NO 2001005607	A	20020117	NO 2001-5607 20011116
US 2003220350	A1	20031127	US 2002-233851

20020830
US 6875760 B2 20050405
US 2005203108 A1 20050915 US 2004-980199
20041103
PRIORITY APPLN. INFO.:
A 19990517 DK 1999-684
A 20000321 DK 2000-478
P 19990517 US 1999-134415P
P 20000323 US 2000-191685P
A3 20000516 US 2000-572553
W 20000516 WO 2000-DK264
A3 20020830 US 2002-233851
OTHER SOURCE(S): MARPAT 134:4764
GI



I



II



III

AB The title compds. [I; V = CO2R2, CONR2R3, CONR2OR3, etc. (wherein R2, R3 = H, alkyl); A = (CH2)n(CR8R9)bNR7, (CR8R9)b(CH2)nNR7, (CR8R9)b(CH2)n,

etc. (b = 0-1; n = 0-3; R7 = H, alkyl, (cycloalkyl)alkyl; R8, R9 = H, alkyl); Y = CO, SO2, O, a bond; Z = (un)substituted phenylene, divalent radical derived from 5-6 membered heteroarom. ring containing 1-2 heteroatoms selected from N, O and S; or AYZ together = II; R1 = H, alkyl; X = CO(CR13R14)r(CH2)s, SO2(CR13R14)r(CH2)s, CO2(CR13R14)r(CH2)s, etc. (r = 0-1; s = 0-3; R13, R14 = H, alkyl); D = (un)substituted Ph, pyridyl, cyclopropyl, etc.; E = (un)substituted quinolinyl, 2,5-dioxopiperidinyl, biphenylalkyl, etc.] which act to antagonize the action of the glucagon hormone on the glucagon receptor (data given), and therefore may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity, were prepared and formulated. E.g., a multi-step solid phase synthesis of III was given. Compds. I are effective at 0.05-10 mg/kg/day.

IT **307988-13-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

RN 307988-13-2 CAPLUS

CN β-Alanine, N-[4-[[[[4-(4-chlorophenyl)-2-thienyl]carbonyl](4-cyclohexylphenyl)amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:535123 CAPLUS Full-text
DOCUMENT NUMBER: 133:150585
TITLE: Preparation of 2,3,4,5-tetrahydro-1H-

[1,4]benzodiazepine-3-hydroxamic acid as matrix

metalloproteinase inhibitors
INVENTOR(S): Albright, Jay Donald; Delos Santos, Efren Guillermo;

Levin, Jeremy Ian; Chen, James Ming
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044730	A1	20000803	WO 2000-US1991	

20000127
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2356267	A1	20000803	CA 2000-2356267	20000127
EP 1147095	A1	20011024	EP 2000-909990	20000127
EP 1147095	B1	20040811		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 2000007759	A	20011113	BR 2000-7759	20000127
TR 200102131	T2	20011221	TR 2001-2131	20000127
HU 200105302	A2	20020729	HU 2001-5302	20000127
JP 2002535392	T	20021022	JP 2000-595986	20000127
US 6544984	B1	20030408	US 2000-492622	20000127
NZ 511885	A	20030630	NZ 2000-511885	20000127
AU 767039	B2	20031030	AU 2000-32160	20000127
AT 273288	T	20040815	AT 2000-909990	20000127
PT 1147095	T	20041231	PT 2000-909990	20000127
ES 2223470	T3	20050301	ES 2000-909990	20000127
ZA 2001004321	A	20020826	ZA 2001-4321	20010525
NO 2001003675	A	20010921	NO 2001-3675	20010726

BG 105736 A 20020531 BG 2001-105736 20010726

PRIORITY APPLN. INFO.: US 1999-198243P P 19990127

US 1999-239080 A 19990127

WO 2000-US1991 W 20000127

OTHER SOURCE(S): MARPAT 133:150585

GI



I



II

AB The title compds. (I) [wherein R = H, alkyl, CN, OH, alkoxy, SH, alkylthio, (O)CF3, Cl, F, NH2, (di)alkylamino, acylamino, NO2, CONH2, or (un)substituted SO2NH2 or alkoxyacetylamino; R1 and R2 = independently H or Me; R3 = alkyl, (un)substituted NH2CH2CO, (hydroxy)acyl, CHO, (hetero)arylacyl, alkoxyacyl, alkylSO2, (hetero)arylalkylSO2, benzyloxycarbonyl, benzoyl, pyridinylcarbonyl, etc.; R4 = (un)substituted alkynyloxy, furanylmethoxy, thiophenylmethoxy, pyrrolylmethoxy, (iso)thiazolylmethoxy, (is)oxazolylmethoxy, or pyrazolylmethoxy] were prepared for the treatment of disease conditions mediated by matrix metalloproteinases (MMP) and TNF-α converting enzyme

(TACE), such as tumor growth, osteoarthritis, rheumatoid arthritis, and degenerative cartilage loss. Examples include syntheses for over 300 intermediates and nearly 90 target compds. (some data given). In vitro gelatinase, collagenase, and TACE inhibition assays are described (some data given). For instance, the Me carboxylate of II (preparation given) was converted to the title N-hydroxy carboxamide II in three steps. II inhibited MMP-1, MMP-9, MMP-13, and TACE with IC50 values of 165 nM, 36 nM, 10 nM, and 59 nM, resp.

IT **233754-56-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetrahydro-1H-[1,4]benzodiazepine-3-hydroxyamic acid MMP and TACE inhibitors by cyclization of 2-[(2-aminobenzyl)amino]acrylates to tetrahydrobenzodiazepine-3-carboxylates and multi-step conversion to the N-hydroxy 3-carboxamides)

RN 233754-56-8 CAPLUS

CN 2-Propenoic acid, 2-[[(4-methoxyphenyl)sulfonyl][[2-[(2-thienylcarbonyl)amino]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:381701 CAPLUS Full-text
DOCUMENT NUMBER: 133:17487
TITLE: Preparation of tetrahydrobenzodiazepine hydroxamic acids as matrix metalloproteinase inhibitors
INVENTOR(S): Albright, Jay D.; Delos, Santos Efren G.; Du, Xuemei
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: U.S., 61 pp., Cont. of U.S. Ser. No. 237,058, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	---	---	---

US 6071903		A	20000606	US 1999-318919 19990526
PRIORITY APPLN. INFO.:				US 1998-93057P P 19980127
				US 1999-237058

B1 19990126
OTHER SOURCE(S): MARPAT 133:17487
GI



I

AB Title compds. [I; R = H, (un)substituted NH2, OH, alkyl, alkoxy, etc.; R1,R2 = H or Me; R3 = (hetero)arylcarbonyl, etc.; R4 = alkoxy, OC6H4R5-4, (un)substituted Ph, etc.; R5 = H, halo, (un)substituted heteroaryl, etc.] were prepared Thus, HOCH2CH(NH2)CO2CMe3(preparation give) was N-acylated by 4-(MeO)C6H4SO2Cl and the product N-alkylated by 2-(O2N)C6H4CH2Br to give serine derivative II (R6 = NO2, R7 = OH, R8 = H) which was reduced and the product N-acylated by 3-(F3C)C6H4COCl to give, after dehydration, II [R6 = 3-(F3C)C6H4CONH, R7R8 = bond]. The latter was cyclized to give, after saponification and amidation, I [R = R1 = R2 = H, R3 = COC6H4(CF3)-3, R4 = OMe]. Data for biol. activity of I were given.

IT **233754-56-8P 233755-58-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(Preparation of tetrahydrobenzodiazepine hydroxamic acids as matrix
metalloproteinase inhibitors)

RN 233754-56-8 CAPLUS
CN 2-Propenoic acid, 2-[[(4-methoxyphenyl)sulfonyl][[2-[(2-

thienylcarbonyl)amino]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)





RN 233755-58-3 CAPLUS
CN 2-Propenoic acid, 2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl][[2-[(2-thienylcarbonyl)amino]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:640697 CAPLUS Full-text
DOCUMENT NUMBER: 131:267045
TITLE: Peptidomimetic antagonists for treatment of CD11/CD18 adhesion receptor-mediated disorders
INVENTOR(S): Burdick, Daniel J.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9949856	A2	19991007	WO 1999-US6410	19990324
WO 9949856	A3	19991118		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2325986	A1	19991007	CA 1999-2325986	19990324
AU 9931137	A	19991018	AU 1999-31137	19990324
AU 764524	B2	20030821		
EP 1063982	A2	20010103	EP 1999-912869	19990324
EP 1063982	B1	20070214		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY

HU 200101587	A2	20010828	HU 2001-1587	19990324
BR 9909418	A	20010925	BR 1999-9418	19990324
NZ 506779	A	20030829	NZ 1999-506779	19990324
EP 1754705	A2	20070221	EP 2006-15229	19990324

R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
NL, PT, SE, AL, LT, LV, MK, RO, SI

AT 353640	T	20070315	AT 1999-912869	19990324
ZA 2000004653	A	20011211	ZA 2000-4653	20000905
NO 2000004800	A	20001124	NO 2000-4800	20000926
US 2005203135	A1	20050915	US 2003-649762	20030826

PRIORITY APPLN. INFO.:

	US 1998-79732P P 19980327
	EP 1999-912869 A3 19990324
	WO 1999-US6410 W 19990324

B1 20000914
OTHER SOURCE(S): MARPAT 131:267045
AB Peptidomimetic compds. (Markush included) that are useful for treating Mac-1- or LFA-1-mediated disorders,e.g. inflammatory disorders, allergies, and autoimmune diseases, are provided.
IT 245465-12-7P 245465-14-9P 245465-33-2P 245465-55-8P 245465-56-9P 245466-38-0P 245466-42-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptidomimetic antagonists for treatment of CD11/CD18 adhesion receptor-mediated disorders)
RN 245465-12-7 CAPLUS
CN L-Alanine, N-[2-chloro-4-[[[1-oxo-3-(2-thienyl)-2-propenyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 245465-14-9 CAPLUS
CN L-Asparagine, N2-[2-chloro-4-[[[1-oxo-3-(2-thienyl)-2-propenyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 245465-33-2 CAPLUS
CN L-Alanine, N-[2-chloro-4-[[[1-oxo-3-(2-thienyl)-2-propenyl]amino]methyl]benzoyl]-3-[[(2-propenyloxy)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 245465-55-8 CAPLUS
CN L-Alanine, 3-amino-N-[2,6-dimethyl-4-[[[1-oxo-3-(2-thienyl)-2-propenyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 245465-56-9 CAPLUS
CN L-Lysine, N2-[2,6-dimethyl-4-[[[1-oxo-3-(2-thienyl)-2-

propenyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 245466-38-0 CAPLUS
CN L-Asparagine, N2-[2-chloro-4-[(1S)-1-[[1-oxo-3-(2-thienyl)-2-
propenyl]amino]ethyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 245466-42-6 CAPLUS
CN L-Alanine, N-[2-chloro-4-[(1S)-1-[[1-oxo-3-(2-thienyl)-2-
propenyl]amino]ethyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L6 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:640160 CAPLUS Full-text
DOCUMENT NUMBER: 131:271803
TITLE: Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
INVENTOR(S): Chan, Ming Fai; Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Kois, Adam; Verner, Erik Joel; Castillo, Rosario Silvestre; Yalamorri, Venkatachalapathi; Balaji, Vitukudi Narayanaiyengar
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 477,223.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962490	A	19991005	US 1996-721183	19960927
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
US 5591761	A	19970107	US 1994-222287	19940405
US 5571821	A	19961105	US 1994-247072	

19940520
US 5594021 A 19970114 US 1995-477223
19950606
WO 9631492 A1 19961010 WO 1996-US4759
19960404
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN
CA 2261760 A1 19980402 CA 1997-2261760
19970926
CA 2261760 C 20050329
WO 9813366 A1 19980402 WO 1997-US17402
19970926
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
UZ, VN, YU, ZW
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG
AU 9745059 A 19980417 AU 1997-45059
19970926
AU 736269 B2 20010726
EP 946552 A1 19991006 EP 1997-943629
19970926
EP 946552 B1 20040707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
CN 1231664 A 19991013 CN 1997-198343
19970926
BR 9711550 A 20000118 BR 1997-11550
19970926

JP 2000507607 19970926	T	20000620	JP 1998-515979
JP 3743520	B2	20060208	
NZ 334797 19970926	A	20010223	NZ 1997-334797
US 6420567 19970926	B1	20020716	US 1997-938325
JP 2002308875 19970926	A	20021023	JP 2002-101613
EP 1342721 19970926	A1	20030910	EP 2003-7240
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL			
AT 270669 19970926	T	20040715	AT 1997-943629
CN 1530366 2003158478 19970926	A	20040922	CN 2003-
PT 946552 19970926	T	20041029	PT 1997-943629
ES 2224271 19970926	T3	20050301	ES 1997-943629
NO 9901388 19990322	A	19990527	NO 1999-1388
US 6331637 19990322	B1	20011218	US 1999-274280
KR 2000048681 19990326	A	20000725	KR 1999-702629
AU 9935803 19990622	A	19990916	AU 1999-35803
AU 726595	B2	20001116	
US 2002091272 20011105	A1	20020711	US 2001-11610
US 6632829	B2	20031014	
US 2003208084 20030528	A1	20031106	US 2003-447763
PRIORITY APPLN. INFO.:			US 1987-100865 A2 19870925
			US 1990-416199 A2 19900515
			US 1993-65202 B2 19930520
			US 1993-100125 B2 19930730
			US 1993-100565 A2 19930730
			US 1993-142159 A2 19931021

A2 19931021	US 1993-142552
B2 19931021	US 1993-142631
A2 19940405	US 1994-222287
A2 19940520	US 1994-247072
A2 19950404	US 1995-417075
A2 19950606	US 1995-477223
A2 19960404	WO 1996-US4759
A 19950404	US 1995-416199
A 19960404	AU 1996-55367
A 19960927	US 1996-721183
A3 19970926	EP 1997-943629
A3 19970926	JP 1998-515979
A3 19970926	US 1997-938325
W 19970926	WO 1997-US17402
A3 20011105	US 2001-11610

OTHER SOURCE(S): MARPAT 131:271803
GI



II



III

AB Thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides, are provided. In

particular, the disclosure includes N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar2SO2NHAr1 [I; Ar1 = (un)substituted aryl, particularly isoxazolyl; Ar2 = biol. effective group for inhibiting endothelin binding by ≥ 50% at ≤100 μM, notably thienyl, furyl, pyrrolyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include hypertension, cardiovascular disease, asthma, hypertension, inflammatory disease, glaucoma, etc. Approx. 190 synthetic examples are given, and numerous example compds. were prepared, tested, and/or claimed. For instance, 5-amino-4-bromo-3-methylisoxazole was treated with NaH in THF, followed by thiophene-2-sulfonyl chloride, to give 34% title compound II. The similarly prepared title compound III had IC50 values of 0.024 μM for ETA receptors and 7.95 μM for ETB receptors, indicating substantial selectivity for ETA.

IT 205516-75-2P, N-[3-[[3-[(4-Chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thienyl]carboxamido]-2,4,6-trimethylbenzoyl]glutamic acid
205516-76-3P, N-[3-[[3-[(4-Chloro-3-methyl-5-isoxazolyl)sulfamoyl]-2-thienyl]carboxamido]-2,4,6-trimethylbenzoyl]aspartic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of thienyl-, furyl- and pyrrolyl-based sulfonamides and analogs as endothelin agonists and antagonists)

RN 205516-75-2 CAPLUS
CN L-Glutamic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-2,4,6-trimethylbenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205516-76-3 CAPLUS
CN L-Aspartic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-2,4,6-trimethylbenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:487279 CAPLUS Full-text
DOCUMENT NUMBER: 131:130010
TITLE: Preparation of 2,3,4,5-tetrahydro-

1H-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors

INVENTOR(S): Albright, Jay Donald; Delos Santos, Efren Guillermo; Du, Xuemei

PATENT ASSIGNEE(S): American Cyanamid Company, USA

SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937625	A1	19990729	WO 1999-US1325	19990122
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2317546	A1	19990729	CA 1999-2317546	19990122
AU 9922402	A	19990809	AU 1999-22402	19990122
BR 9907746	A	20001017	BR 1999-7746	19990122
EP 1051407	A1	20001115	EP 1999-902417	19990122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002501056	T	20020115	JP 2000-528549	19990122

HU 200100277 A2 20020228 HU 2001-277 19990122
ZA 9900569 A 20000726 ZA 1999-569 19990126
NO 2000003828 A 20000926 NO 2000-3828 20000726
PRIORITY APPLN. INFO.: US 1998-14374 A 19980127
WO 1999-US1325 W 19990122
OTHER SOURCE(S): MARPAT 131:130010
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. having formula [I; R = H, C1-3 alkyl, cyano, OR', SR', CF3, OCF3, Cl, F, NH2, C1-3 alkyl-amino, C1-3-alkyl-CONR', NR'R', NO2, CONH2, SO2NH2, SO2NR'R', C1-3 alkyl-OCH2CONR'; wherein R' = C1-3 alkyl, H; R4 = Q, Q1, Q2, Q3, Q4; wherein X = O, S; R'' = H, halo, cyano, Me, OMe; R1, R2 = H, Me; R3 = C1-8 alkyl, NH2CH2CO, C1-6 alkyl-NHCH2CO, HO(CH2)mCO, CHO, aryl-(CH2)nCO, heteroaryl-(CH2)nCO, C1-3 alkyl-O(CH2)nCO, C1-3-alkyl-CO, C1-3 alkyl-CONHCH2CO, C3-7 cycloalkyl-CO, C1-3 alkyl-SO2, etc.; wherein m = 1-3; n = 0-3], which are useful for the treatment of disease conditions mediated by matrix metalloproteinases, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss, are prepared Thus, to a solution of 0.556 mmol of 4-(4-methoxybenzenesulfonyl)-1- (3-trifluoromethylbenzoyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylic acid (preparation given) in 5 mL of CH2Cl2, was added 1.11 mmol of 2.0 M oxalyl chloride in CH2Cl2 and 0.044 mL of N,N-dimethylformamide. The mixture was stirred under nitrogen at room temperature for 1.5 h and cooled in an ice bath, treated with a chilled mixture of 2.24 mmol hydroxylamine hydrochloride and 3.36 mmol of triethylamine in 1.39 mL of THF and 0.33 mL of H2O, and stirred at room temperature overnight to give the title compound (II; R5 = CF3). II (R5 = H) in vitro showed IC50 of 15.8, 0.56, 0.4, and 95±10 nM against interstitial collagenase (MMP-1),

gelatinase (MMP-9), MMP-13, and TNF-α converting enzyme (TACE), resp.

IT 233754-56-8P 233755-58-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydrobenzodiazepinehydroxamic acids as matrix metalloproteinase inhibitors for treating matrix metalloproteinases-mediated disease conditions)

RN 233754-56-8 CAPLUS
CN 2-Propenoic acid, 2-[[(4-methoxyphenyl)sulfonyl][[2-[(2-thienylcarbonyl)amino]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)





RN 233755-58-3 CAPLUS
CN 2-Propenoic acid, 2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl][[2-[(2-thienylcarbonyl)amino]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:206866 CAPLUS Full-text
DOCUMENT NUMBER: 130:291600
TITLE: Amides, bone formation promoters containing them, and their use as antiosteoporotic agents
INVENTOR(S): Shibata, Saizo; Omori, Fujimi; Nakagawa, Takashi
PATENT ASSIGNEE(S): Japan Tobacco, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 45 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.

DATE

JP 11080107	A	19990326	JP 1997-251360	19970901

PRIORITY APPLN. INFO.: JP 1997-251360 19970901

OTHER SOURCE(S): MARPAT 130:291600

GI



AB Bone formation promoters contain amides I [W = H, amino, NHCOR3 (R3 = lower alkyl), lower alkoxycarbonyl, cycloalkyl, naphthyl, morpholino, thienyl, phthalimido, benzoyl, benzyloxy, C6H4R4 (R4 = H, halo, lower alkyl, lower alkoxy); Y = O, NHCO2, NHCO, CONH, CO, CO2, OCO, CO(CH:CH)u (u = 1, 2), direct bond; ring A = benzene, naphthalene, cyclohexane, biphenyl, di-Ph ether, pyridine, isoxazole, thiophene; R1 = H, halo, NO2, lower alkyl, lower alkoxy; R2 = H, lower alkyl; Z = halo, OH, lower alkyl, lower alkoxy, lower alkoxycarbonyl, carboxy, NR5R6 [R5, R6 = H, (hydroxy)alkyl, aryl, lower alkylcarbonyl], N+R7R8R9 [R7, R8 = lower alkyl, aralkyl; R9 = lower alkyl, (halo)aralkyl, arylcarbonylalkyl], SR10 (R10 = lower alkyl, aralkyl), SO2R11 (R11 = lower alkyl, aralkyl), SOR12 (R12 = lower alkyl, aralkyl), S+R13R14 (R13, R14 = lower

alkyl), morpholino, pyridyl, pyridinio, Q (R15 = lower alkyl), Q1 (R16 = lower alkyl), Q2 (R17 = lower alkyl), Q3 (R18 = lower alkyl); R2 and R5 may be bonded to each other to form Q4 (R6 = any group given above); R2 and R7 may be bonded to each other to form Q5 (R8, R9 = any group given above), m = 0-20; n = 0-4] or their pharmaceutically acceptable salts as active ingredients. Pharmaceutical compns. and antiosteoporotic agents containing I or their salts are also claimed. N-[2-(dimethylamino)ethyl]4-(nonyloxy)benzamide hydrochloride (preparation given) at 3 μM showed 244% osteoblast growth promoting activity.

IT 222979-36-4P 222979-38-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)aromatic amides as bone formation promoters for treatment of osteoporosis)

RN 222979-36-4 CAPLUS
CN β-Alanine, N-[4-[[5-(2-thienyl)pentyl]oxy]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 222979-38-6 CAPLUS
CN β-Alanine, N-[4-[[5-(2-thienyl)pentyl]oxy]benzoyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:113654 CAPLUS Full-text
DOCUMENT NUMBER: 130:168653
TITLE: Preparation of methionine-containing aniline-derived sulfonamides as inhibitors of protein farnesyl transferase (PFTase) and geranylgeranyl transferase (GGTase)
INVENTOR(S): Gotteland, Jean-Pierre; Halazy, Serge; Perrin, Dominique; Hill, Bridget
PATENT ASSIGNEE(S): Pierre Fabre Medicament, Fr.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO. DATE
WO 9906376	A1	19990211	WO 1998-FR1694 19980730
W: AU, BR, CA, CN, JP, MX, US			
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
FR 2766819	A1	19990205	FR 1997-9802 19970731
FR 2766819	B1	19991029	
AU 9889852	A	19990222	AU 1998-89852 19980730

PRIORITY APPLN. INFO.: FR 1997-9802 A 19970731
WO 1998-FR1694

W 19980730
OTHER SOURCE(S): MARPAT 130:168653
GI



I



II

AB Title compds. [I; R1 = specified 4-mercaptopyrrolidin-2-yl, 5-oxopyrrolidin-2-yl, 5-thioxopyrrolidin-2-yl, thiazolidinyl-4-yl, 2-oxothiazolidin-4-yl, 2-thioxothiazolidin-4-yl, etc.; R2 = (un)saturated C1-20 alkyl, aryl, alkylaryl, (alkyl)heteroaryl, CF3, NO2, CN, Cl, F, Br, OCF3, OH, SH, OR9, SR9, NHR9R10, COR9, CONR9R10, COOR9, NHCOR9; R9, R10 = C1-5 alkyl, aryl, heteroaryl; X = (CH2)n, CO, (CH2)nCO, CO(CH2)n; n = 1-5; R3 = H, F, Cl, Br, I, CF3, SiMe3, OH, SH, OR11, SR11; R11 = aryl, heteroaryl; R4 = CH2CH2SMe, CH2CH2S(O)Me, CH2CH2SO2Me, CH2OH, CH2CH2OH, iso-Bu, sec-Bu, Bu, CH2OMe, CH2CH2OMe, CH2CH:CH2, CH2SH, CH2SMe, CH2SCH2Ph, CH2CH2SPh, CH2CH2S(2-thienyl), (CH2)mNHCOMe, (CH2)mNH2, (CH2)mNHMe, (CH2)mNMe2; m = 1-4; R5 = H, (branched) alkyl] and their pharmacol. acceptable salts were prepared For example, title sulfonamide II was prepared (preparation not given but product characterizing NMR data provided), and it inhibited PFTase with IC50 = 20 nM.

IT 220452-89-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of methionine-containing, aniline-derived sulfonamides as inhibitors of protein farnesyl transferase and geranylgeranyl transferase)

RN 220452-89-1 CAPLUS
CN L-Methionine, N-[[5-[(1H-imidazol-4-ylmethyl)(2-thienylcarbonyl)amino][1,1'-biphenyl]-2-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:744942 CAPLUS Full-text
DOCUMENT NUMBER: 130:25339
TITLE: Inhibitors of protein isoprenyl transferases
INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Donner, Bernard G.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce G.; Tasker, Andrew S.; Wasick, James I.; Winn, Martin
PATENT ASSIGNEE(S): University of Pittsburgh, USA

SOURCE: PCT Int. Appl., 618 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850031	A1	19981112	WO 1998-US9298	19980507
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9873719	A	19981127	AU 1998-73719	19980507
TW 492955	B	20020701	TW 1998-87107182	19980715
TW 541302	B	20030711	TW 1998-87107183	19980715

PRIORITY APPLN. INFO.: US 1997-852858 A 19970507
WO 1998-US9298 W 19980507
OTHER SOURCE(S): MARPAT 130:25339

AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is absent or is L4NR5L5, L4OL5, L4S(O)mL5 (m = 0-2), etc., where L4 and L5 are absent or alkylene, alkenylene, R5 is H, alkanoyl; Z is a covalent bond, O, S(O)q (q = 0-2), NH or imino; R3 = H, aryl, fluorenyl, heterocyclyl, cycloalkyl, etc.] were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-(2-thienylmethoxymethyl)-2-(2-methylphenyl)benzoyl]methionine lithium salt, prepared

via amidation reaction, showed 96% inhibition of farnesyltransferase at 1x10-6 M.

IT 216088-62-9P 216088-63-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitors of protein isoprenyl transferases)

RN 216088-62-9 CAPLUS
CN L-Methionine, N-[[2'-methyl-5-[(2-thienylmethoxy)methyl][1,1'-biphenyl]-2-yl]carbonyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216088-63-0 CAPLUS
CN L-Methionine, N-[[2'-methyl-5-[(3-thienylmethoxy)methyl][1,1'-biphenyl]-2-yl]carbonyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

IT 216086-56-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(inhibitors of protein isoprenyl transferases)
RN 216086-56-5 CAPLUS
CN L-Methionine, N-[[2'-methyl-5-[(2-thienylmethoxy)methyl][1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:744940 CAPLUS Full-text
DOCUMENT NUMBER: 130:25338
TITLE: Inhibitors of protein isoprenyl transferases

INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Donner, Bernard G.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce G.; Tasker, Andrew S.; Wasick, James I.; Winn, Martin

PATENT ASSIGNEE(S): University of Pittsburgh, USA

SOURCE: PCT Int. Appl., 848 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850029	A1	19981112	WO 1998-US9296	19980507
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2288330	A1	19981112	CA 1998-2288330	19980507
AU 9874733	A	19981127	AU 1998-74733	19980507
EP 986384	A1	20000322	EP 1998-922122	

19980507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2002518985 T 20020625 JP 1998-548480 19980507
TW 492955 B 20020701 TW 1998-87107182 19980715
TW 541302 B 20030711 TW 1998-87107183 19980715
MX 9910186 A 20000630 MX 1999-10186 19991105
PRIORITY APPLN. INFO.: US 1997-852858 A 19970507
WO 1998-US9296 W 19980507
OTHER SOURCE(S): MARPAT 130:25338
AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is absent or is L4NR5L5, L4OL5, L4S(O)mL5 (m = 0-2), etc., where L4 and L5 are absent or alkylene, alkenylene, R5 is H, alkanoyl; Z is a covalent bond, O, S(O)q (q = 0-2), NH or imino; R3 = H, aryl, fluorenyl, heterocyclyl, cycloalkyl, etc.] were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-[(R)-thiazolidin-4- ylcarbonylamino]-2-phenylbenzoyl]methionine Me ester hydrochloride, prepared via amidation reaction, showed 92% inhibition of farnesyl transferase at 1x10-6 M.
IT 216229-74-2P 216229-83-3P 216232-14-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of inhibitors of protein isoprenyl transferases)
RN 216229-74-2 CAPLUS
CN Butanoic acid, 4-(methylsulfonyl)-2-[[[5-[[(2-thienylmethyl)amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216229-83-3 CAPLUS
CN Butanoic acid, 4-(methylsulfonyl)-2-[[[5-[[[2-(2-thienyl)ethyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216232-14-3 CAPLUS
CN 3-Thiophenecarboxylic acid, 4-[[[6-[[[(1S)-1-carboxy-3-(methylthio)propyl]amino]carbonyl]-2'-methyl[1,1'-biphenyl]-3-yl]methyl]amino]-, 3-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:210751 CAPLUS Full-text
DOCUMENT NUMBER: 128:270601
TITLE: Preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators
INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy P.; Blok, Natalie; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813366	A1	19980402	WO 1997-US17402	19970926
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5962490	A	19991005	US 1996-721183	19960927
CA 2261760	A1	19980402	CA 1997-2261760	19970926
CA 2261760	C	20050329		

AU 9745059 19970926	A	19980417	AU 1997-45059
AU 736269	B2	20010726	
EP 946552 19970926	A1	19991006	EP 1997-943629
EP 946552	B1	20040707	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9711550 19970926	A	20000118	BR 1997-11550
JP 2000507607 19970926	T	20000620	JP 1998-515979
JP 3743520	B2	20060208	
NZ 334797 19970926	A	20010223	NZ 1997-334797
AT 270669 19970926	T	20040715	AT 1997-943629
NO 9901388 19990322	A	19990527	NO 1999-1388
AU 9935803 19990622	A	19990916	AU 1999-35803
AU 726595	B2	20001116	

PRIORITY APPLN. INFO.:	US 1996-721183
A 19960927	US 1987-100865
A2 19870925	US 1990-416199
A2 19900515	US 1993-65202
B2 19930520	US 1993-100125
B2 19930730	US 1993-100565
A2 19930730	US 1993-142159
A2 19931021	US 1993-142552
A2 19931021	US 1993-142631
B2 19931021	US 1994-222287
A2 19940405	US 1994-247072
A2 19940520	US 1995-417075
A2 19950404	US 1995-477223

A2 19950606

A 19960404

A2 19960404

W 19970926

AU 1996-55367

WO 1996-US4759

WO 1997-US17402

OTHER SOURCE(S): MARPAT 128:270601

GI



I

AB R1SO2NHR [I; R = (un)substituted (hetero)aryl; R1 = R2Z2Z1; R2 = (un)substituted Ph; Z1 = thiophene-, furan-, pyrrole-2,3- or -3,2-diyl, etc.; Z2 = COCH2, CONH, CO2, CH:CH, CH2O, etc.] were prepared Thus, 2-methoxycarbonyl-3-thiophenesulfonyl chloride was amidated by 5-amino-4-chloro-3-methylisoxazole and the product converted in 5 steps to title compound II. Data for biol. activity of I were given.

IT 205516-75-2P 205516-76-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators)

RN 205516-75-2 CAPLUS

CN L-Glutamic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-2,4,6-

trimethylbenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205516-76-3 CAPLUS
CN L-Aspartic acid, N-[3-[[[3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]-2,4,6-trimethylbenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 37 OF 44 CAPLUS

ACCESSION NUMBER: 1997:151429 CAPLUS Full-text
DOCUMENT NUMBER: 126:157495
TITLE: Preparation of pyridopyridine derivatives as tachykinin antagonists
INVENTOR(S): Natsukari, Hideaki; Ishimaru, Takenori; Doi, Takayuki
PATENT ASSIGNEE(S): Takeda Chemical Industries Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08337583	A	19961224	JP 1996-115519	19960412

PRIORITY APPLN. INFO.: JP 1995-113594 A 19950413
OTHER SOURCE(S): MARPAT 126:157495
GI For diagram(s), see printed CA Issue.
AB The title compds. I [ring A, B = homocyclic ring, heterocyclic ring; at least one of rings A and B is a heterocyclic ring; Z = heterocyclic ring, etc.; R = H, hydrocarbon; one of X and Y is NR1 or O, the other is CO or CS; or one of X and Y is N, the other is CR2; R1 = H, hydrocarbon; R2 = H, halo, etc.; n = 1 - 4], useful as tachykinin antagonists (no data), are prepared For example, 7,8-dihydro-7-methyl-5-(4-methylphenyl)-8-oxo-N-(2- pyridylmethyl)-6-pyrido[3,4-b]pyridinecarboxamide was prepared
IT 168542-26-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyridopyridine derivs. as tachykinin antagonists)
RN 168542-26-5 CAPLUS
CN Glycine, N-methyl-N-[2-(2-thienylcarbonyl)benzoyl]-, ethyl ester (9CI)
(CA INDEX NAME)



L6 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:474202 CAPLUS Full-text
DOCUMENT NUMBER: 125:211155
TITLE: Lanthanide(III) complexes with a Schiff base derived from 4-aminohippuric acid and 2-thiophenealdehyde: synthesis and mouse sperm inhibition activity
AUTHOR(S): Shen, Xu; Li, Quan; Yang, Chuanjun; Xie, Yuyuan
CORPORATE SOURCE: Shanghai Institute Materia Medica, Academia Sinica, Shanghai, 200031, Peop. Rep. China
SOURCE: Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (1996), 26(7), 1135-1147
CODEN: SRIMCN; ISSN: 0094-5714
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Twelve lanthanide(III) complexes, Ln(TBG)3·nH2O [where Ln = La, Ce, Pr, Sm, Eu, Gd, Tb, Dy, Ho, Er, Yb, n = 3; Ln = Nd, n = 4; HTBG = 4-(2'-thiophenaldiminobenzoyl)glycine], were synthesized and characterized by elemental analyses, magnetic moment and molar conductance measurements, IR, UV and 1H NMR spectra as well as TGA and DSC methods. Preliminary pharmacol. tests showed mouse-sperm inhibition activity for the Sm complex.

IT **181184-83-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with rare earth salts)
RN 181184-83-8 CAPLUS
CN Glycine, N-[4-[(2-thienylmethylene)amino]benzoyl]-,

monosodium salt (9CI)
(CA INDEX NAME)



● Na

IT 181184-82-7DP, lanthanide complexes 181184-82-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 181184-82-7 CAPLUS
CN Glycine, N-[4-[(2-thienylmethylene)amino]benzoyl]-
(9CI) (CA INDEX NAME)



RN 181184-82-7 CAPLUS
CN Glycine, N-[4-[(2-thienylmethylene)amino]benzoyl]-
(9CI) (CA INDEX NAME)



L6 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:994147 CAPLUS Full-text
DOCUMENT NUMBER: 124:55567

TITLE: Preparation of substituted benzene-derivative endothelin inhibitors

INVENTOR(S): Astles, Peter Charles; Harper, Mark Francis; Harris, Neil Victor; McLay, Ian McFarlane; Walsh, Roger John Aitchison; Lewis, Richard Alan; Smith, Christopher; Porter, Barry; McCarthy, Clive

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Ltd., UK

SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9513262	A1	19950518	WO 1994-GB2499	19941114
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2176363	A1	19950518	CA 1994-2176363	19941114
AU 9481498	A	19950529	AU 1994-81498	19941114
ZA 9409035	A	19960514	ZA 1994-9035	19941114
EP 728128	A1	19960828	EP 1995-900842	19941114
EP 728128	B1	19980916		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09505043	T	19970520	JP 1995-513704	19941114

AT 171158 T 19981015 AT 1995-900842
19941114
ES 2123941 T3 19990116 ES 1995-900842
19941114
US 6211234 B1 20010403 US 1997-640922
19970627
PRIORITY APPLN. INFO.: GB 1993-23382
A 19931112
GB 1994-3363
A 19940222
GB 1994-10750
A 19940527
WO 1994-GB2499
W 19941114
OTHER SOURCE(S): MARPAT 124:55567
GI



I

AB The title compds. [I; R1 = H, (un)substituted hydroxyalkyl, carboxyalkyl, CN, NO2, (un)substituted alkoxy, etc.; R2 = arylalkoxy, heteroarylalkoxy, arylalkylthio, etc.; R3 = HO, alkoxy, aryloxy, etc.; R4 = (un)substituted alkyl or alkenyl; R5 = alkyl, alkenyl, halogen; m-p = 0, 1], useful as endothelin inhibitors (no data) for the treatment of diseases modulated by inhibiting endothelin (no data), are prepared Thus, Me 2-benzyloxy-4-(4-chlorobenzyloxyl)benzoate was saponified, producing 2-benzyloxy-4-(4- chlorobenzyloxy)benzoic acid, m.p. 150-152°, in 44% yield.

IT 170282-28-7P 170282-29-8P 170282-31-2P
170282-35-6P 170282-38-9P 170282-39-0P
170282-66-3P 170282-68-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of substituted benzene endothelin inhibitors)

RN 170282-28-7 CAPLUS

CN Glycine, N-[2-hydroxy-4-(3-thienylmethoxy)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 170282-29-8 CAPLUS

CN Glycine, N-[4-(3-thienylmethoxy)-2-[[2-(trimethylsilyl)ethoxy]methoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 170282-31-2 CAPLUS

CN β-Alanine, N-[2-hydroxy-4-(3-thienylmethoxy)benzoyl]-,

methyl ester
(9CI) (CA INDEX NAME)



RN 170282-35-6 CAPLUS
CN β-Alanine, N-[4-(3-thienylmethoxy)-2-[[2-(trimethylsilyl)ethoxy]methoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 170282-38-9 CAPLUS
CN D-Phenylalanine, N-[4-(3-thienylmethoxy)-2-[2-(trimethylsilyl)ethoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170282-39-0 CAPLUS
CN L-Phenylalanine, N-[4-(3-thienylmethoxy)-2-[2-(trimethylsilyl)ethoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170282-66-3 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[[1-(methoxycarbonyl)ethenyl]amino]carbo
nyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX
NAME)



RN 170282-68-5 CAPLUS
CN L-Serine, N-[4-(3-thienylmethoxy)-2-[[2-[(trimethylsilyl)oxy]ethoxy]methoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 170280-85-0P 170280-86-1P 170280-90-7P
170281-00-2P 170281-04-6P 170281-31-9P
170281-32-0P 170281-34-2P 170281-70-6P
170281-71-7P 170281-72-8P 170283-23-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzene endothelin inhibitors)
RN 170280-85-0 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(2-carboxyethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl- (9CI) (CA INDEX

NAME)



RN 170280-86-1 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(carboxymethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 170280-90-7 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(2-methoxy-2-oxoethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 170281-00-2 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(2-methoxy-2-oxoethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 170281-04-6 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(3-methoxy-3-oxopropyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 170281-31-9 CAPLUS

CN Benzenebutanoic acid, γ-[2-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170281-32-0 CAPLUS

CN Benzenebutanoic acid, γ-[2-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, α-ethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170281-34-2 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(1-carboxyethenyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 170281-70-6 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170281-71-7 CAPLUS

CN Benzenebutanoic acid, γ-[2-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170281-72-8 CAPLUS

CN Benzenebutanoic acid, γ-[2-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170283-23-5 CAPLUS
CN Benzenebutanoic acid, γ-[2-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-5-(3-thienylmethoxy)phenoxy]-2-methyl-, α-ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:835514 CAPLUS Full-text
DOCUMENT NUMBER: 123:256684
TITLE: Preparation of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compounds as tachykinin antagonists and inhibitors of plasma

extravasation.

INVENTOR(S): Natsugari, Hideaki; Ishimaru, Takenori; Doi, Takayuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 652218	A1	19950510	EP 1994-117576	19941108
EP 652218	B1	20010711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
NO 9404252	A	19950511	NO 1994-4252	19941108
AT 203024	T	20010715	AT 1994-117576	19941108
CA 2135440	A1	19950511	CA 1994-2135440	19941109
FI 9405281	A	19950511	FI 1994-5281	19941109
AU 9477738	A	19950518	AU 1994-77738	19941109
AU 678295	B2	19970522		
BR 9404403	A	19950718	BR 1994-4403	19941109
JP 08067678	A	19960312	JP 1994-274699	19941109
RU 2135471	C1	19990827	RU 1994-40174	19941109
HU 68810	A2	19950519	HU 1994-3230	19941110
CN 1107476	A	19950830	CN 1994-113866	19941110
CN 1052004	B	20000503		
US 5585385	A	19961217	US 1994-338762	19941110
BR 9501976	A	19960430	BR 1995-1976	19950509

PRIORITY APPLN. INFO.: JP 1993-281178

A 19931110 JP 1993-337488

A 19931228 JP 1994-33637

A 19940303 JP 1994-138551

A 19940621

OTHER SOURCE(S): CASREACT 123:256684; MARPAT 123:256684

GI For diagram(s), see printed CA Issue.

AB Title compds. [I; ring A, ring B = (substituted) homo- or heterocyclyl, ≥1 of them = (substituted) heterocyclyl; ring C = (substituted) benzene ring; R = H, (substituted) hydrocarbyl; 1 of X, Y = NR1, O; the other = CO, CS; or 1 of them = N: and the other = :CR2; R1 = H, (substituted) hydrocarbyl; R2 = H, halo, (substituted) hydrocarbyl, amino, OH; n = 1, 2], were prepared Thus, 5-(4-fluorophenyl)-7,8-dihydro-7-methyl- 8-oxo-6-pyrido[3,4-b]pyridinecarboxylic acid (preparation given) was refluxed with SOCl2 in benzene and ther residue in THF was refluxed with N-[3,5-bis(trifluoromethyl)benzyl]methylamine and Et3N to give N-[3,5-bis(trifluoromethyl)benzyl]-5-(4-fluorophenyl)-7,8-dihydro-N,7-di methyl-8-oxo-6-pyrido[3,4-b]pyridinecarboxamide (II). II inhibited substance P binding to IM-9 human lymphoblasts with IC50 = 0.08 nM. Tablets containing II were prepared

IT 168542-26-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compds. as tachykinin antagonists and inhibitors of plasma extravasation)

RN 168542-26-5 CAPLUS

CN Glycine, N-methyl-N-[2-(2-thienylcarbonyl)benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:786283 CAPLUS Full-text
DOCUMENT NUMBER: 124:56589
TITLE: Polymer-supported Mitsunobu ether formation and its use in combinatorial chemistry
AUTHOR(S): Krchnak, Viktor; Flegelova, Zuzka; Weichsel, Aleksandra S.; Lebl, Michal
CORPORATE SOURCE: Selectide Corp., Tucson, AZ, 85737, USA
SOURCE: Tetrahedron Letters (1995), 36(35), 6193-6
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Arom. hydroxy acids, Ac-Tyr-OH and N-(4-hydroxybenzoyl)glycine, were attached to a polymeric solid support and the phenolic hydroxy groups reacted with a variety of primary and secondary alcs. under the conditions of the Mitsunobu reaction (triphenylphosphine and di-Et azodicarboxylate) in THF. In most cases the reaction provided a nearly quant. yield of alkyl aryl ethers, as determined after cleaving the product from the resin. To demonstrate that the polymer-supported Mitsunobu reaction is useful for combinatorial library synthesis, the authors synthesized a number of model compds. and a simple three randomization step library composed of 4,200 different compds.
IT 171814-11-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(polymer-supported Mitsunobu etherification and use in combinatorial chemical)
RN 171814-11-2 CAPLUS
CN Glycine, N-[4-(2-thienylmethoxy)benzoyl]- (9CI) (CA

INDEX NAME)



L6 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:76603 CAPLUS Full-text
DOCUMENT NUMBER: 112:76603
TITLE: Preparation of acylphenol derivatives as analgesics, antiinflammatories, and antipyretics
INVENTOR(S): Kise, Masahiro; Yoshimoto, Yoshihiko; Fujisawa, Hiroshi; Sasaki, Yasuo; Yasufuku, Shoji
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO. DATE
EP 331195	A2	19890906	EP 1989-103780 19890303
EP 331195	A3	19901128	
R: DE, IT, NL, SE			
GB 2216515	A	19891011	GB 1989-1863 19890127
CN 1044651	A	19900815	CN 1989-100665 19890131
ES 2013035	A6	19900416	ES 1989-623 19890221
US 4927835	A	19900522	US 1989-317601 19890301
FR 2628105	A1	19890908	FR 1989-2697

19890302
BE 1002868 A4 19910709 BE 1989-215
19890302
JP 03215456 A 19910920 JP 1989-50297
19890302
HU 54617 A2 19910328 HU 1989-1035
19890303
PRIORITY APPLN. INFO.: JP 1988-51977
A 19880304
OTHER SOURCE(S): CASREACT 112:76603; MARPAT 112:76603
GI



I



Q

AB Title compds. I [R1 = cycloalkyl, (substituted) aryl, Q (A = O, S, NR5; R5 = H, alkyl; R6 = H, alkyl, halo); R2 = alkyl, cycloalkyl; R3, R4 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R3R4N = cyclic amino] are prepared A mixture of 3-(1,1-dimethylethyl)-4-hydroxyphenyl 2-thienyl ketone, N-methylethanolamine, 35% aqueous HCHO, AcOH and EtOH was refluxed to give I [R1 = 2-thienyl, R2 = Me3C, R3 = HO(CH2)2, R4 = Me]. The latter showed an ED30 of 9.8 mg/kg for inhibiting carrageenin-induced edema in rats, vs. 0.8 mg for indomethacin.

IT **124979-01-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as analgesic, antiinflammatory, and antipyretic)

RN 124979-01-7 CAPLUS
CN Glycine, N-[[3-(1,1-dimethylethyl)-2-hydroxy-5-(2-thienylcarbonyl)phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1982:7043 CAPLUS Full-text
DOCUMENT NUMBER: 96:7043
TITLE: Synthesis and some physicochemical properties of diethyl p-aminobenzoyl-L-glutamate azomethines
AUTHOR(S): Nikolaeva, C. L.; Borukhova, I. N.; Andreeva, N. A.; Pushkareva, Z. V.
CORPORATE SOURCE: USSR
SOURCE: Deposited Doc. (1980), SPSTL 556khp-D80, 10 pp.
Avail.: SPSTL
DOCUMENT TYPE: Report
LANGUAGE: Russian
AB Title azomethines 4-[RCH:N]C6H4CO-Glu(OEt)-OEt [R = 2-naphthyl, 2-thienyl, 2-furyl, 5-nitro-2-furyl, 1,2,3,4-tetrahydro-6-hydroxy-2,4-dioxo-5- pyrimidinyl, 1,2,3,4-tetrahydro-6-hydroxy-4-oxo-2-thioxo-5-pyrimidinyl, 1,2,3,4-tetrahydro-2,4-dioxo-6-pyrimidinyl, 2-HOC6H4] were prepared by condensation of 4-H2NC6H4CO-Glu(OEt)-OEt with aldehydes. The azomethines possessed dihydrofolate reductase inhibiting activities, and their polarog. reduction potentials were close to that of folic acid.
IT **80064-81-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and dihydrofolate reductase inhibiting activity of)
RN 80064-81-9 CAPLUS
CN L-Glutamic acid, N-[4-[(2-thienylmethylene)amino]benzoyl]-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L6 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1968:487446 CAPLUS Full-text
DOCUMENT NUMBER: 69:87446
TITLE: Synthesis of N-[p-[(2-naphthyl- and
N-[p-[(2-thienylmethyl)amino]benzoyl]-DL-glutamic acid
AUTHOR(S): Gurina, S. L.; Batulina, R. Kh.; Alekseeva, L. V.;
Pushkareva, Z. V.
CORPORATE SOURCE: Ural. Politekh. Inst. im. Kirova, Sverdlovsk, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1968), (3),
431-2
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB A mixt. of 1.1 g. 2-(bromomethyl)naphthalene, 1.65 g. di-Et N-(p-aminobenzoyl)-DL-glutamate (I), 0.5 g. NaHCO3, a few crystals of NaI, and 15 ml. EtOH was refluxed 15 hrs. on a water bath and filtered, the solvent evaporated, the residue treated with 10 ml. EtOH and 1.5 ml. 30% NaOH, and the mixture kept 3 hrs. at room temperature and neutralized with HCl to give a gummy product, which was washed with water, dried over P2O5, powdered, and purified by dissolving in aqueous NaHCO3 and precipitating with HCl to give 0.72 g. N-[p-(2-naphthylmethyl)amino]benzoyl]-DL-glutamic acid, m. 93-7°. A mixture of 1.32 g. 2-(chloromethyl)thiophene, 3.2 g. I, 1 g. Et3N, and 25 ml. anhydrous C6H6 was heated for 5 hrs. and filtered,

the filtrate evaporated in vacuo, and the residue dissolved in 20 ml. EtOH with 2 ml. 40% NaOH and worked up as above to give 1.85 g. N-[p-[(2-thienylmethyl)amino]benzoyl]- DL-glutamic acid, m. 70-95°.

IT **19641-89-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19641-89-5 CAPLUS

CN Glutamic acid, N-[p-(2-thenylamino)benzoyl]-, DL- (8CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	233.29	448.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-	34.32 -34.32

STN INTERNATIONAL LOGOFF AT 10:22:42 ON 29 MAY 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:13:12 ON 31 MAY 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:13:50 ON 31 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 MAY 2007 HIGHEST RN 936211-93-7
DICTIONARY FILE UPDATES: 30 MAY 2007 HIGHEST RN 936211-93-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\105008111.str





chain nodes :
1 2 3 4 5 6 27 28 32
ring nodes :
7 8 9 10 11 12 17 18 19 20 21 22 23 24 25 26
chain bonds :
1-2 1-3 1-4 4-5 5-6 6-9 18-27 24-28
ring bonds :
7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-21 18-19 19-20 20-21 22-23 22-26
23-24 24-25 25-26
exact/norm bonds :
1-2 1-3 1-4 4-5 5-6 6-9 17-18 17-21 18-19 18-27 19-20 20-21 22-23
22-26 23-24 24-25 24-28 25-26
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12

G1:[*1],[*2]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 32:CLASS 33:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 08:14:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4556 TO ITERATE

43.9% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 87073 TO 95167
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 08:14:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 90406 TO ITERATE

100.0% PROCESSED 90406 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.05

L3 5 SEA SSS FUL L1

=> s l3 and caplus/lc
54326390 CAPLUS/LC
L4 5 L3 AND CAPLUS/LC

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 177.05 177.26

FILE 'CAPLUS' ENTERED AT 08:14:33 ON 31 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 31 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 30 May 2007 (20070530/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l4
L5 4 L4

=> d ibib abs hitstr 1-4

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:587882 CAPLUS
DOCUMENT NUMBER: 141:140439
TITLE: Preparation of substituted 2-phenylbenzimidazoles as antidiabetics
INVENTOR(S): Streicher, Ruediger; Mack, Juergen; Walter, Rainer; Konetzki, Ingo; Trieselmann, Thomas; Austel, Volkhard
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
SOURCE: Ger. Offen., 63 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10300398	A1	20040722	DE 2003-10300398	20030109
CA 2512813	A1	20040729	CA 2003-2512813	20031223
WO 2004062663	A1	20040729	WO 2003-EP14760	20031223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003292263	A1	20040810	AU 2003-292263	20031223
US 2005014810	A1	20050120	US 2003-744830	20031223
US 7151114	B2	20061219		
EP 1585517	A1	20051019	EP 2003-767827	20031223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515857	T	20060608	JP 2004-566023	20031223

PRIORITY APPLN. INFO.:

DE 2003-10300398	A	20030109
US 2003-499522P	P	20030902
WO 2003-EP14760	W	20031223

OTHER SOURCE(S): MARPAT 141:140439
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Benzimidazoles I [R1 = substituted Ph; R2 = (un)substituted aryl, heteroaryl, CONH2, NO2; R3 = H; R2R3 = (un)substituted N:CHN:CH; R4-R6 = H, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy] were prepared for use as glucagon receptor antagonists in the treatment of diabetes. Thus, the benzimidazole II was prepared by amidating 4,3-F(O2N)C6H3CO2H with 1-aminoethylcyclohexene, amination with (+)-dehydroabietylamine, reduction of the nitro group and the cyclohexene ring, and cyclization with

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
3-OCHC6H4OCH2CO2H.
IT 727399-46-4P 727399-56-6P 727399-64-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 2-phenylbenzimidazoles as antidiabetics)
RN 727399-46-4 CAPLUS
CN β-Alanine, N-[3-[1-[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]-5-(2-thienyl)-1H-benzimidazol-2-yl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727399-56-6 CAPLUS
CN β-Alanine, N-[3-(5-chloro-2-thienyl)-1-[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]-1H-benzimidazol-2-yl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727399-64-6 CAPLUS
CN β-Alanine, N-[3-[5-(5-methyl-2-thienyl)-1-[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]-1H-benzimidazol-2-yl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:244899 CAPLUS
DOCUMENT NUMBER: 140:423617
TITLE: Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles
AUTHOR(S): Vickerstaffe, Emma; Warrington, Brian H.; Ladlow, Mark; Ley, Steven V.
CORPORATE SOURCE: GlaxoSmithKline Cambridge Technology Centre, University Chemical Laboratory, Cambridge, CB2 1EW, UK
SOURCE: Journal of Combinatorial Chemistry (2004), 6(3), 332-339
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:423617
AB The polymer-assisted solution-phase (PASP) synthesis of a 192-member 2-D array of 1,5-diarylpyrazoles is reported. The synthesis was performed in a fully automated manner using a multiprobe top-filtration robot and incorporates a catch and release step to afford library compds. directly in high yield and purity.
IT 692735-44-7P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(fully automated polymer-assisted synthesis of 1,5-diarylpyrazoles)
RN 692735-44-7 CAPLUS
CN Glycine, N-[4-[5-(2-thienyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:591190 CAPLUS
DOCUMENT NUMBER: 139:149756
TITLE: Preparation of N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as EDG receptor agonists
INVENTOR(S): Doherty, George A.; Li, Zhen; Hale, Jeffrey J.; Mills, Sander G.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062248	A2	20030731	WO 2003-US1059	20030114
WO 2003062248	A3	20060302		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472713	A1	20030731	CA 2003-2472713	20030114
JP 2005527494	T	20050915	JP 2003-562125	20030114
EP 1575964	A2	20050921	EP 2003-702110	20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005020837	A1	20050127	US 2004-500811	20040707
PRIORITY APPLN. INFO.:			US 2002-349995P	P 20020118
			WO 2003-US1059	W 20030114

OTHER SOURCE(S): MARPAT 139:149756
AB The present invention encompasses preparation of compds., A(CR1R2)nNHCHR3Ar[(R4)0-4]BC (Ar = Ph, naphthyl, etc.; A = CO2H, 1H-tetrazol-5-yl, PO3H2, PO2H2, SO3H, PO(R5)OH, R5 = C1-4 alkyl, hydroxyC1-4alkyl, Ph, COC1-3alkoxy, CH(OH)Ph, etc.; n = 2-4; R1, R2 = independently selected from H, halo, OH, CO2H, C1-6 alkyl, Ph, etc.; R3 = H, C1-4 alkyl, etc.; R4 = CO2H, C1-4 alkyl, sulfonylalkyl, alkoxy, alkoxycyclopropyl, aryl, aryloxy, etc.; C = C1-8 alkyl, C1-8 alkoxy, heterocyclyl, etc.; B = (un)substituted Ph, (un)substituted C5-16 alkyl, (un)substituted C5-16 alkenyl, (un)substituted C5-16 alkynyl, etc.), as well as the pharmaceutically acceptable salts and hydrates thereof. The compds. are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compns. and methods of use are included. Thus, reaction of 3-aminopropylphosphonic acid with 4-(decyloxy)benzaldehyde in presence of Bu4NOH and sodium cyanoborohydride in MeOH for 1h at 50° gave title compound, N-((4-decyloxy)benzyl)-3-aminopropylphosphonic acid.
IT 569684-79-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as EDG receptor agonists)
RN 569684-79-3 CAPLUS
CN Butanoic acid, 4-[[[4-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1,2,4-oxadiazol-3-yl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:590932 CAPLUS
DOCUMENT NUMBER: 139:149413
TITLE: Selective S1P1/Edg1 receptor agonists
INVENTOR(S): Doherty, George A.; Forrest, Michael J.; Hajdu, Richard; Hale, Jeffrey J.; Li, Zhen; Mandala, Suzanne M.; Mills, Sander G.; Rosen, Hugh; Scolnick, Edward M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061567	A2	20030731	WO 2003-US1120	20030114
WO 2003061567	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004058894	A1	20040325	US 2003-339380	20030109
CA 2472680	A1	20030731	CA 2003-2472680	20030114
EP 1469863	A2	20041027	EP 2003-731917	20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005070506	A1	20050331	US 2004-501176	20040712
PRIORITY APPLN. INFO.:			US 2002-349991P	P 20020118
			US 2002-362566P	P 20020307
			US 2002-382933P	P 20020523
			WO 2003-US1120	W 20030114

AB The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Thus, 4-HOC6H4CHO was treated with Me(CH2)7I to give 4-Me(CH2)7OC6H4CHO which was treated with H2N(CH2)3P(O)(OH)2 to give 4-Me(CH2)7OC6H4CH2NH(CH2)3P(O)(OH)2 which had an EC50 for S1P1 agonism of 1.5 nM and for S1P3 agonism of 6.0 nM.
IT 569684-79-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino functionalized organo phosphonates or organo carboxylates as S1P1/Edg1 receptor agonists)
RN 569684-79-3 CAPLUS
CN Butanoic acid, 4-[[[4-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1,2,4-oxadiazol-3-yl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.49	199.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

STN INTERNATIONAL LOGOFF AT 08:16:04 ON 31 MAY 2007